WORLD PEPTIDEFOUNDATION

Where is Teduglutide being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for Teduglutide →Worldwide registry directory

Scientific intelligence record

Experience 2.0

GLP-2 analog

Teduglutide

Teduglutide is a GLP-2 analog studied in short bowel syndrome and intestinal failure. The clinical question concerns outcomes such as parenteral support and patient experience in defined populations.

Record status

Traceability partial

Last meaningful update: 9/26/2026

Evidence searched through:
Not recorded
Assessment updated:
9/26/2026
Documented human review:
No documented human review recorded
Automated scientific assessment:
None recorded
AI source check:
9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

393

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

0

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

6

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

185

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observationArchive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

393

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

0

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

6

Independent evidence dossiers covering the major research questions.

Published source records

185

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

0

Conflicting evidence relationships that remain visible.

Research gaps

1

Questions the current record identifies as unresolved.

Connected media

0

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

6 published domain syntheses connected to 0 featured studies

Teduglutide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas
Inspect the published evidence record185 governed records · titles, provenance, and original-source linksOpen records ↓
2023Phase 3 human evidence

Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension.

Content-verified record concerning Teduglutide: "Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension." Abstract excerpt: The short- and long-term efficacy, safety, and pharmacokinetics of teduglutide were analyzed in adult Japanese patients with short bowel syndrome and intestinal failure (SBS-IF). Patients received teduglutide 0.05 mg/kg/day in clinical trials (TED-C14-004, SHP633-306, and extension SHP633-307). Data were analyzed at 24 weeks and an interim data cut-off of 4.5 years. The parenteral s

Source
peer_reviewed_research
DOI
10.1007/s00595-022-02587-4
PubMed
36201060
Open original source
2020Phase 3 human evidence

Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.

Content-verified record concerning Teduglutide: "Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study." Abstract excerpt: This study evaluated the safety and efficacy of teduglutide in pediatric patients with short bowel syndrome-associated intestinal failure (SBS-IF). A 24-week, phase III trial with 2 randomized, double-blind teduglutide dose groups and a nonblinded standard of care (SOC) arm was used; patients received 0.025 mg/kg or 0.05 mg/kg teduglutide once daily. Safety end points included treatment-

Source
peer_reviewed_research
DOI
10.1002/jpen.1690
PubMed
31495952
Open original source
2015Phase 3 human evidence

Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials.

Content-verified record concerning Teduglutide: "Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials." Abstract excerpt: In clinical trials, treatment with the glucagon-like peptide 2 analog teduglutide was associated with improved fluid and nutrient absorption and increased intestinal villus height and crypt depth in patients with short bowel syndrome (SBS). Plasma citrulline, an amino acid produced by enterocytes, is considered a measure of enterocyte mass. This analysis assessed changes in plasma citrulline level

Source
peer_reviewed_research
DOI
10.1038/ctg.2015.15
PubMed
26111125
Open original source
2013Phase 1–2 human evidence

Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.

Content-verified record concerning Teduglutide: "Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study." Abstract excerpt: Short bowel syndrome (SBS)-intestinal failure (IF) patients have impaired quality of life (QoL) and suffer from the burden of malabsorption and parenteral support (PS). A phase III study demonstrated that treatment with teduglutide, a glucagon-like peptide 2 analogue, reduces PS volumes by 32% while maintaining oral fluid intake constant; placebo-treated patients had reduced PS by 21%, but oral fl

Source
peer_reviewed_research
DOI
10.1016/j.clnu.2013.03.016
PubMed
23587733
Open original source
2022Phase 1–2 human evidence

Teduglutide for the treatment of low-output enterocutaneous fistula - A pilot randomized controlled study.

Content-verified record concerning Teduglutide: "Teduglutide for the treatment of low-output enterocutaneous fistula - A pilot randomized controlled study." Abstract excerpt: Enterocutaneous fistula (ECF) is a complication of surgery or inflammatory bowel disease associated with disproportionately high healthcare costs, morbidity, and mortality. We performed this proof-of-concept, feasibility, open-label, pilot randomized, crossover study to assess the efficacy and safety of the use of teduglutide (TED) to treat ECF. Adults (age >18) with low-output (<200 mL

Source
peer_reviewed_research
DOI
10.1016/j.clnesp.2022.04.031
PubMed
35871951
Open original source
2011Phase 1–2 human evidence

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.

Content-verified record concerning Teduglutide: "Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome." Abstract excerpt: Teduglutide, a GLP-2 analogue, may restore intestinal structural and functional integrity by promoting repair and growth of the mucosa and reducing gastric emptying and secretion, thereby increasing fluid and nutrient absorption in patients with short bowel syndrome (SBS). This 24-week placebo-controlled study evaluated the ability of teduglutide to reduce parenteral support in patients with SBS w

Source
peer_reviewed_research
DOI
10.1136/gut.2010.218271
PubMed
21317170
Open original source
2017Phase 1–2 human evidence

Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide.

Content-verified record concerning Teduglutide: "Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide." Abstract excerpt: Narcotic agents are frequently administered to manage increased intestinal motility in patients with short bowel syndrome, but long-term use is associated with gastrointestinal (GI) complaints. This analysis evaluated the incidence of narcotic use and abdominal adverse events among patients with short bowel syndrome receiving teduglutide. Pooled data from patients who received ≥1 dose of te

Source
peer_reviewed_research
DOI
10.1177/0148607116663481
PubMed
27507402
Open original source
2014Phase 1–2 human evidence

A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.

Content-verified record concerning Teduglutide: "A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects." Abstract excerpt: Teduglutide, a recombinant analog of human glucagon-like peptide (GLP)-2, is a novel therapy recently approved for the treatment of adult patients with short bowel syndrome who are dependent on parenteral support. Previous studies assessing the effect of GLP-2 on gastric emptying in humans have yielded inconsistent results, with some studies showing no effect and others documenting a GLP-2-depende

Source
peer_reviewed_research
DOI
10.1186/1471-230x-14-25
PubMed
24517114
Open original source
2020Phase 1–2 human evidence

Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study.

Content-verified record concerning Teduglutide: "Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study." Abstract excerpt: Disease-associated factors influence parenteral support (PS) reduction in response to teduglutide in patients with intestinal failure associated-short bowel syndrome (SBS-IF). We sought to determine correlative relationships between plasma citrulline levels, small bowel length, and PS volume. A post hoc analysis of plasma citrulline levels from patients in the STEPS 24-week study of teduglutide in

Source
peer_reviewed_research
DOI
10.1016/j.clnu.2019.11.001
PubMed
31784300
Open original source
2018Observational human evidence

Further improvement after 24-month treatment with teduglutide in a patient with active Crohn's disease and short bowel syndrome.

Content-verified record concerning Teduglutide: "Further improvement after 24-month treatment with teduglutide in a patient with active Crohn's disease and short bowel syndrome." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.5152/tjg.2018.17596
PubMed
29749341
Open original source
2020Observational human evidence

GLP-2 analog Teduglutide in active Crohn's disease and short bowel syndrome: Confirmation of anti-inflammatory role and future perspectives.

Content-verified record concerning Teduglutide: "GLP-2 analog Teduglutide in active Crohn's disease and short bowel syndrome: Confirmation of anti-inflammatory role and future perspectives." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1016/j.dld.2020.03.019
PubMed
32340888
Open original source
2017Observational human evidence

Enteral Autonomy with Teduglutide Treatment of Intestinal Failure/Short Bowel Syndrome with Depleted Central Venous Access.

Content-verified record concerning Teduglutide: "Enteral Autonomy with Teduglutide Treatment of Intestinal Failure/Short Bowel Syndrome with Depleted Central Venous Access." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1007/s10620-017-4780-y
PubMed
28993968
Open original source
2026Observational human evidence

Teduglutide use in haemodialysis-dependent renal failure from secondary hyperoxaluria in short bowel syndrome and type 3 intestinal failure - A case report.

Content-verified record concerning Teduglutide: "Teduglutide use in haemodialysis-dependent renal failure from secondary hyperoxaluria in short bowel syndrome and type 3 intestinal failure - A case report." Abstract excerpt: Renal impairment is common in patients receiving long-term home parenteral nutrition (HPN) for short bowel syndrome-associated intestinal failure (SBS-IF). While glucagon-like peptide-2 (GLP-2) analogues like teduglutide are effective in reducing parenteral support (PS) requirements, data on their use in advanced stage chronic kidney disease (CKD) or haemodialysis are scarce. We describe a 66-year

Source
peer_reviewed_research
DOI
10.1016/j.intf.2026.100364
PubMed
41852601
Open original source
2025Observational human evidence

Teduglutide in adults with short bowel syndrome and intestinal failure: A descriptive cohort study.

Content-verified record concerning Teduglutide: "Teduglutide in adults with short bowel syndrome and intestinal failure: A descriptive cohort study." Abstract excerpt: International evidence supports the efficacy of teduglutide in reducing parenteral support requirements, or achieving enteral autonomy, in patients with short bowel syndrome-intestinal failure. This is a multicenter observational study presenting the real-world experience with teduglutide in Australia. 11 of 12 Australian intestinal rehabilitation units submitted data for 19 adult patients with sh

Source
peer_reviewed_research
DOI
10.1002/jpen.2786
PubMed
40515554
Open original source
2024Observational human evidence

Use of Teduglutide in the Management of Gastrointestinal Graft-versus-Host Disease in Children and Young Adults.

Content-verified record concerning Teduglutide: "Use of Teduglutide in the Management of Gastrointestinal Graft-versus-Host Disease in Children and Young Adults." Abstract excerpt: Loss of intestinal L cells and reduced levels of glucagon-like peptide-2 (GLP-2) have been implicated in acute graft-versus-host disease (GVHD) in murine models. Teduglutide, a human recombinant GLP-2 analog, may be beneficial in acute gastrointestinal (GI) GVHD owing to its known tissue protective and regenerative functions. We retrospectively reviewed patients who received teduglutide for treatm

Source
peer_reviewed_research
DOI
10.1016/j.jtct.2024.01.080
PubMed
38311212
Open original source
2024Observational human evidence

Effect of teduglutide, a glucagon-like peptide-2 analog, in eosinophilic enterocolitis: a case report.

Content-verified record concerning Teduglutide: "Effect of teduglutide, a glucagon-like peptide-2 analog, in eosinophilic enterocolitis: a case report." Abstract excerpt: We successfully treated a 4-year-old girl with short bowel syndrome and eosinophilic enterocolitis with teduglutide, a glucagon-like peptide-2 analog. Her eosinophilic enterocolitis was cured without relapse, and we were able to increase enteral nutrition. We found that teduglutide had an anti-inflammatory effect in this patient with eosinophilic gastrointestinal disease associated with short bowe

Source
peer_reviewed_research
DOI
10.3389/fped.2024.1457824
PubMed
39439449
Open original source
2019Observational human evidence

Off-Label Teduglutide Therapy in Non-intestinal Failure Patients with Chronic Malabsorption.

Content-verified record concerning Teduglutide: "Off-Label Teduglutide Therapy in Non-intestinal Failure Patients with Chronic Malabsorption." Abstract excerpt: Teduglutide, a glucagon-like peptide 2 analog, has demonstrated efficacy in treating adult patients with short bowel syndrome (SBS) and dependence on parenteral nutrition (PN), but its role in chronic malabsorptive states that do not necessitate PN remains uncertain. To evaluate teduglutide use beyond its approved indications and to discuss the results of this adjunctive treatment in patients resi

Source
peer_reviewed_research
DOI
10.1007/s10620-019-5473-5
PubMed
30730014
Open original source
2025Observational human evidence

Efficacy of Teduglutide in Pediatric Short Bowel Syndrome: Association with Citrulline Levels and Anatomical Location of Remnant Small Intestine.

Content-verified record concerning Teduglutide: "Efficacy of Teduglutide in Pediatric Short Bowel Syndrome: Association with Citrulline Levels and Anatomical Location of Remnant Small Intestine." Abstract excerpt: Background/Objectives: Short bowel syndrome (SBS) is the leading cause of pediatric intestinal failure. Plasma citrulline is considered a marker indicating an enterocyte volume and may help evaluate the response to teduglutide; however, this interpretation may vary depending on the remnant bowel anatomy. Methods: We conducted a retrospective case series of four pediatric patients with SBS (aged &l

Source
peer_reviewed_research
DOI
10.3390/children12080977
PubMed
40868429
Open original source
2024Observational human evidence

Early use of teduglutide in paediatric patients with intestinal failure is associated with a greater response rate: a multicenter study.

Content-verified record concerning Teduglutide: "Early use of teduglutide in paediatric patients with intestinal failure is associated with a greater response rate: a multicenter study." Abstract excerpt: Teduglutide is a glucagon-like-peptide-2 analogue that reduces the need for parenteral support in patients with short bowel syndrome (SBS). Nevertheless, data about long-term therapy with teduglutide in children are still scarce. Our objective was to describe the real-life experience with teduglutide in children with SBS over the last 5 years in Spain. This was a national multicentre and pros

Source
peer_reviewed_research
DOI
10.1007/s00431-024-05577-5
PubMed
38664251
Open original source
2024Observational human evidence

The Impact of Teduglutide on Real-Life Health Care Costs in Children with Short Bowel Syndrome.

Content-verified record concerning Teduglutide: "The Impact of Teduglutide on Real-Life Health Care Costs in Children with Short Bowel Syndrome." Abstract excerpt: To analyze the real-life health care costs of home parenteral nutrition (HPN) in children with short bowel syndrome with intestinal failure (SBS-IF) before and after treatment with teduglutide, and to compare those with costs of children with SBS-IF not treated with teduglutide. All consecutive children with SBS-IF on HPN treated with subcutaneous teduglutide starting from 2018 through 2020 in a t

Source
peer_reviewed_research
DOI
10.1016/j.jpeds.2023.113882
PubMed
38135030
Open original source
2026Observational human evidence

Clinical outcomes of teduglutide therapy in children with short bowel syndrome-associated intestinal failure: A single-center experience.

Content-verified record concerning Teduglutide: "Clinical outcomes of teduglutide therapy in children with short bowel syndrome-associated intestinal failure: A single-center experience." Abstract excerpt: Short bowel syndrome-associated intestinal failure (SBS-IF) requires long-term parenteral nutrition (PN), increasing the risk of complications such as central line associated bloodstream infections, sepsis and liver disease. Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, has been shown to enhance intestinal adaptation and reduce PN dependence, but long-term real-world data in children are

Source
peer_reviewed_research
DOI
10.1016/j.intf.2026.100382
PubMed
42318325
Open original source
2022Observational human evidence

Long-term results of teduglutide treatment for chronic intestinal failure - Insights from a national, multi-centric patient home-care service program.

Content-verified record concerning Teduglutide: "Long-term results of teduglutide treatment for chronic intestinal failure - Insights from a national, multi-centric patient home-care service program." Abstract excerpt: Teduglutide is a Glucagon-like peptide-2 (GLP-2) agonist indicated for the treatment of patients with parenteral support (PS) dependent short bowel syndrome (SBS) with chronic intestinal failure (cIF). Its application is accompanied by a structured nation-wide home-care service program in Germany. We investigated care characteristics and outcome parameters in a clinical real-world observational se

Source
peer_reviewed_research
DOI
10.1016/j.clnesp.2022.08.027
PubMed
36184208
Open original source
2024Observational human evidence

Cost-effectiveness of teduglutide in adult patients with short bowel syndrome - a European socioeconomic perspective.

Content-verified record concerning Teduglutide: "Cost-effectiveness of teduglutide in adult patients with short bowel syndrome - a European socioeconomic perspective." Abstract excerpt: Short bowel syndrome with intestinal failure (SBS-IF) is a rare but devastating medical condition. An absolute loss of bowel length forces the patients into parenteral support dependency and a variety of medical sequelae, resulting in increased morbidity and mortality. Interdisciplinary treatment may include therapy with the effective but expensive intestinotrophic peptide teduglutide. A time-disc

Source
peer_reviewed_research
DOI
10.1016/j.ajcnut.2024.02.031
PubMed
38431119
Open original source
2023Observational human evidence

Post-Marketing Use of Teduglutide in a Large Cohort of Adults with Short Bowel Syndrome-Associated Chronic Intestinal Failure: Evolution and Outcomes.

Content-verified record concerning Teduglutide: "Post-Marketing Use of Teduglutide in a Large Cohort of Adults with Short Bowel Syndrome-Associated Chronic Intestinal Failure: Evolution and Outcomes." Abstract excerpt: Teduglutide, a GLP-2 analogue, has been available in France since 2015 to treat short-bowel-syndrome (SBS)-associated chronic intestinal failure (CIF) but it remains very expensive. No real-life data on the number of potential candidates are available. The aim of this real-life study was to assess teduglutide initiation and outcomes in SBS-CIF patients. All SBS-CIF patients cared for in an expert

Source
peer_reviewed_research
DOI
10.3390/nu15112448
PubMed
37299413
Open original source
2020Observational human evidence

Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study.

Content-verified record concerning Teduglutide: "Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study." Abstract excerpt: Teduglutide, a GLP-2-analog, has proven effective in two placebo-controlled studies in reducing parenteral support (PS) in patients with short bowel syndrome-associated intestinal failure (SBS-IF) after 24 weeks. The aim of this study was to describe in a real-life situation the effects of teduglutide treatment and their predictive factors. We included 54 consecutive SBS-IF patients treated with t

Source
peer_reviewed_research
DOI
10.1016/j.clnu.2019.12.019
PubMed
31932048
Open original source
2023Observational human evidence

Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications.

Content-verified record concerning Teduglutide: "Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications." Abstract excerpt: Microscopic colitis is a chronic inflammatory condition of the colon characterized by chronic watery diarrhea, generally with endoscopically normal or nonspecific findings, and can be diagnosed by histopathological examination of colon mucosal biopsies. Some patients experience severe symptoms that do not respond to conventional medical treatment. A glucagon-like peptide-2 (GLP-2) analog, teduglut

Source
peer_reviewed_research
DOI
10.3389/fmed.2023.1231565
PubMed
37649980
Open original source
2018Observational human evidence

Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series.

Content-verified record concerning Teduglutide: "Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series." Abstract excerpt: To review all cases of parenteral support (PS)-dependent patients with short bowel syndrome (SBS) treated with teduglutide (Gattex, Shire) and to evaluate its efficacy and adverse effects. This is a retrospective descriptive cohort of SBS patients treated with teduglutide. Demographics, bowel length, primary diagnosis, PS volume/duration, teduglutide dose, and side effects were collected prospecti

Source
peer_reviewed_research
DOI
10.1002/jpen.1149
PubMed
29603279
Open original source
2017Observational human evidence

Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.

Content-verified record concerning Teduglutide: "Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure." Abstract excerpt: Teduglutide is a GLP-2 analogue indicated for treatment of adults with short bowel syndrome (SBS). Because of the rarity of SBS, real-world safety or efficacy data are not available in patients with Crohn's disease (CD) and SBS treated with teduglutide. To evaluate teduglutide's safety and efficacy in CD patients with SBS. We conducted a retrospective cohort study at 3 tertiary centers in the Unit

Source
peer_reviewed_research
DOI
10.1097/mcg.0000000000000604
PubMed
27433811
Open original source
2021Observational human evidence

Long-Term Outcomes With Teduglutide From a Single Center.

Content-verified record concerning Teduglutide: "Long-Term Outcomes With Teduglutide From a Single Center." Abstract excerpt: The aim of this study was to quantify the long-term clinical outcomes for individuals receiving teduglutide for short-bowel syndrome (SBS). A single-center, retrospective study was performed for individuals commencing use of teduglutide between March 2013 and May 2019. Eighteen patients were included in the final analysis, among which the median duration of teduglutide administration was 3.2 (rang

Source
peer_reviewed_research
DOI
10.1002/jpen.1838
PubMed
32391948
Open original source
2026Observational human evidence

Real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure.

Content-verified record concerning Teduglutide: "Real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure." Abstract excerpt: Patients with short bowel syndrome-associated intestinal failure (SBS-IF) require parenteral nutrition and/or intravenous fluids (PN/IV); however, long-term dependence can lead to complications. Teduglutide enhances mucosal growth and the absorptive function of the residual intestine and reduces dependence on PN/IV. We aimed to investigate the use of teduglutide in real-world settings. This retros

Source
peer_reviewed_research
DOI
10.1016/j.clnesp.2026.103359
PubMed
42167731
Open original source
2025Observational human evidence

Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey.

Content-verified record concerning Teduglutide: "Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey." Abstract excerpt: Teduglutide is a glucagon-like peptide-2 analogue used to promote intestinal rehabilitation and decrease the dependence from intravenous supplementation (IVS) in patients with short bowel syndrome and intestinal failure (SBS-IF). The aim of this study was to gain a better understanding of international real-world Teduglutide use since its launch. Data from an international multicenter database for

Source
peer_reviewed_research
DOI
10.1016/j.clnu.2025.01.026
PubMed
39986179
Open original source
2026Observational human evidence

Successful treatment with teduglutide in short bowel syndrome with intestinal failure secondary to small-bowel volvulus: a case report and literature review.

Content-verified record concerning Teduglutide: "Successful treatment with teduglutide in short bowel syndrome with intestinal failure secondary to small-bowel volvulus: a case report and literature review." Abstract excerpt: Short bowel syndrome (SBS) is a major cause of intestinal failure (IF). Patients with SBS-associated IF (SBS-IF) often require long-term parenteral nutrition (PN) and suffer from complications that impair quality of life (QoL), including severe diarrhea, weight loss, sleep disturbances, and catheter-related bloodstream infections (CRBSIs). Teduglutide, a glucagon-like peptide-2 analog, enhances in

Source
peer_reviewed_research
DOI
10.1097/rc9.0000000000000863
PubMed
42699525
Open original source
2025Observational human evidence

Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey.

Content-verified record concerning Teduglutide: "Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey." Abstract excerpt: Intestinal glucocorticoid-refractory (SR) acute (a) graft-versus-host disease (GVHD) causes high non-relapse mortality (NRM) in patients after allogeneic hematopoietic cell transplantation (allo-HCT). Recent preclinical data indicate that acute GVHD causes a loss of intestinal neuroendocrine L-cells leading to reduced levels of glucagon-like peptide-2 (GLP-2). GLP-2 substitution improved GVHD seve

Source
peer_reviewed_research
DOI
10.1038/s41409-025-02586-2
PubMed
40229535
Open original source
2021Observational human evidence

Teduglutide Therapy in 2 Patients With Short-Bowel Syndrome and Familial Adenomatous Polyposis.

Content-verified record concerning Teduglutide: "Teduglutide Therapy in 2 Patients With Short-Bowel Syndrome and Familial Adenomatous Polyposis." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1002/jpen.2001
PubMed
32829492
Open original source
2019Observational human evidence

Teduglutide in Patients With Active Crohn's Disease and Short Bowel Syndrome.

Content-verified record concerning Teduglutide: "Teduglutide in Patients With Active Crohn's Disease and Short Bowel Syndrome." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1093/ibd/izz087
PubMed
30990222
Open original source
2023Observational human evidence

Use of teduglutide for short bowel syndrome and Crohn's disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy.

Content-verified record concerning Teduglutide: "Use of teduglutide for short bowel syndrome and Crohn's disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy." Abstract excerpt: Surgery in Crohn's disease may be the cause of short bowel syndrome that may lead to kidney dysfunction. Dual biologic therapy is rarely needed to control activity. We present a case of a 61-year-old steroid dependent (A2L1B3p) female who had undergone surgery on three occasions: ileocecal resection (resection of 15 cm of terminal ileum); resection of right and left colon up to sigmoid; proctectom

Source
peer_reviewed_research
DOI
10.17235/reed.2022.9194/2022
PubMed
36177820
Open original source
2019Observational human evidence

Effect of teduglutide on restoring oral autonomy for magnesium in two patients with short bowel.

Content-verified record concerning Teduglutide: "Effect of teduglutide on restoring oral autonomy for magnesium in two patients with short bowel." Abstract excerpt: It is not known whether Teduglutide can allow patients with Short bowel syndrome, previously dependent on continuous or periodic intravenous (IV) magnesium, to attain oral autonomy with or without supplementation. Here, we report on two patients previously dependent on continuous or intermittently administered IV magnesium to achieve autonomy from IV, one with and one without oral supplementation

Source
peer_reviewed_research
DOI
10.1016/j.nut.2019.02.014
PubMed
31029916
Open original source
2022Observational human evidence

Characterization of American teduglutide consumers from 2015 to 2020: A large database study.

Content-verified record concerning Teduglutide: "Characterization of American teduglutide consumers from 2015 to 2020: A large database study." Abstract excerpt: Teduglutide, a glucagon-like peptide-2 analog, is a novel therapy for intestinal failure that reduces need for parenteral support, especially in patients without a functional terminal ileum or colon. It can also predispose patients to accelerated progression of gastrointestinal (GI) malignancy and fluid overload. We demographically and clinically characterized American patients prescribed teduglut

Source
peer_reviewed_research
DOI
10.1002/jpen.2221
PubMed
34291485
Open original source
2025Observational human evidence

Forty-eight months outcomes of teduglutide treatment in adult stable patients with short bowel syndrome and home parenteral nutrition dependence: A real-world Italian single-center observational cohort study.

Content-verified record concerning Teduglutide: "Forty-eight months outcomes of teduglutide treatment in adult stable patients with short bowel syndrome and home parenteral nutrition dependence: A real-world Italian single-center observational cohort study." Abstract excerpt: This real-life study is designed to investigate the short and long-term efficacy and safety of teduglutide (TED) and its effects on the quality of life (QoL) in a cohort of adult, stable patients with short bowel syndrome and chronic intestinal failure receiving long-term parenteral support (PS). A prospective, single-center study was conducted for individuals who began to take TED between March 2

Source
peer_reviewed_research
DOI
10.1016/j.nut.2024.112640
PubMed
39689615
Open original source
2026Observational human evidence

Outcomes and adverse effects of teduglutide treatment with periodic withdrawal in pediatric short bowel patients.

Content-verified record concerning Teduglutide: "Outcomes and adverse effects of teduglutide treatment with periodic withdrawal in pediatric short bowel patients." Abstract excerpt: We evaluated the efficacy and safety of teduglutide in a real-world cohort in which national reimbursement policies required treatment interruptions. The primary outcomes were reduction in parenteral support (PS) and treatment-related adverse effects, and the secondary outcome was the impact of the mandated withdrawal periods. In this retrospective registry-based nationwide study, we identified al

Source
peer_reviewed_research
DOI
10.1002/jpn3.70437
PubMed
41954179
Open original source
2023Observational human evidence

Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure.

Content-verified record concerning Teduglutide: "Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure." Abstract excerpt: The short-term effects of teduglutide (TED) for short bowel syndrome with chronic intestinal failure (SBS-IF) in patients with Crohn's disease (CD) remain unknown. The aim of this study was to investigate the effects of TED in patients with CD on home parenteral support (PS) for SBS-IF. We retrospectively investigated the medical records of patients with CD associated with SBS-IF who initiated TED

Source
peer_reviewed_research
DOI
10.1016/j.clnu.2023.03.012
PubMed
37001195
Open original source
2024Observational human evidence

Reversal of Intestinal Failure With Teduglutide in <i>PERCC1</i>-Associated Enteropathy: A Case Report.

Content-verified record concerning Teduglutide: "Reversal of Intestinal Failure With Teduglutide in <i>PERCC1</i>-Associated Enteropathy: A Case Report." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.7326/m24-0147
PubMed
38710080
Open original source
2017Observational human evidence

Results of 12-month rescue treatment with Teduglutide in severely active and parenteral nutrition-dependent Crohn's disease.

Content-verified record concerning Teduglutide: "Results of 12-month rescue treatment with Teduglutide in severely active and parenteral nutrition-dependent Crohn's disease." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.5152/tjg.2016.0587
PubMed
27991856
Open original source
2021Observational human evidence

Imaging as predictor of clinical response to teduglutide in adult patients with short bowel syndrome with chronic intestinal failure.

Content-verified record concerning Teduglutide: "Imaging as predictor of clinical response to teduglutide in adult patients with short bowel syndrome with chronic intestinal failure." Abstract excerpt: Teduglutide (TED) is a glucagon-like peptide 2 analogue approved in patients with short bowel syndrome with chronic intestinal failure. Bowel epithelial hyperplasia has been reported after TED treatment. The aim of this study was to describe small bowel modifications at imaging in patients with SBS-CIF receiving TED and to assess their predictive value for clinical response. Monocentric retrospect

Source
peer_reviewed_research
DOI
10.1093/ajcn/nqaa412
PubMed
33675349
Open original source
2021Observational human evidence

Long-term Effects of Teduglutide on Intestinal Mucosa in a Patient With Crohn's Disease and Short Bowel Syndrome: Clinical, Endoscopic and Histological Data Compared.

Content-verified record concerning Teduglutide: "Long-term Effects of Teduglutide on Intestinal Mucosa in a Patient With Crohn's Disease and Short Bowel Syndrome: Clinical, Endoscopic and Histological Data Compared." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1093/ibd/izab171
PubMed
34255043
Open original source
2020Observational human evidence

Small-Bowel Adaptation: A Case of Morphological Changes Induced by Teduglutide in Short-Bowel Syndrome With Intestinal Failure.

Content-verified record concerning Teduglutide: "Small-Bowel Adaptation: A Case of Morphological Changes Induced by Teduglutide in Short-Bowel Syndrome With Intestinal Failure." Abstract excerpt: Teduglutide (TED) reduces the need for parenteral support (PS) in patients with short-bowel syndrome with intestinal failure (SBS-IF). It is a glucagon-like peptide-2 analog that improves absorption, induces the expansion of the absorptive epithelium in the small intestine, and may be used in patients with SBS-IF after a 6- to 12-month adaptation period, if PS is always necessary. We described the

Source
peer_reviewed_research
DOI
10.1002/jpen.1805
PubMed
32187383
Open original source
2020Observational human evidence

Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series.

Content-verified record concerning Teduglutide: "Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series." Abstract excerpt: Teduglutide promotes intestinal growth and is approved for the treatment of short bowel syndrome and intestinal failure (SBS-IF). Based on the pharmacologic activity and preclinical findings, teduglutide can potentially induce proliferative colonic mucosal changes. The aim of this study is to report the occurrence of colorectal polyps in adult patients with SBS-IF who received teduglutide in

Source
peer_reviewed_research
DOI
10.1016/j.clnu.2019.08.020
PubMed
31522784
Open original source
2024Observational human evidence

Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry.

Content-verified record concerning Teduglutide: "Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry." Abstract excerpt: The Short Bowel Syndrome (SBS) Registry (NCT01990040) is a multinational real-world study evaluating the long-term safety of teduglutide in patients with SBS and intestinal failure (SBS-IF) in routine clinical practice. This paper describes the study methodology and baseline characteristics of adult patients who have (ever-treated) or have never (never-treated) received teduglutide. A total of 141

Source
peer_reviewed_research
DOI
10.3390/nu16152513
PubMed
39125394
Open original source
2021Observational human evidence

De Novo Development of Distal Jejunal and Duodenal Adenomas After 41 Months of Teduglutide Treatment in a Patient With Short-Bowel Syndrome: A Case Report.

Content-verified record concerning Teduglutide: "De Novo Development of Distal Jejunal and Duodenal Adenomas After 41 Months of Teduglutide Treatment in a Patient With Short-Bowel Syndrome: A Case Report." Abstract excerpt: The glucagon-like peptide-2 (GLP-2) analogue teduglutide is a medical treatment option for patients with short-bowel syndrome-associated chronic intestinal failure. Because studies in mice have shown that GLP-2 analogues may promote the growth of colonic neoplasms, surveillance colonoscopies before and during teduglutide therapy were recommended. The occurrence of small-intestinal neoplasms has no

Source
peer_reviewed_research
DOI
10.1002/jpen.1982
PubMed
32740933
Open original source
2026Observational human evidence

Growth trajectories of children with short bowel syndrome during the first year of teduglutide treatment.

Content-verified record concerning Teduglutide: "Growth trajectories of children with short bowel syndrome during the first year of teduglutide treatment." Abstract excerpt: Short bowel syndrome (SBS) is the leading cause of pediatric intestinal failure and is frequently associated with impaired growth due to malabsorption and prolonged dependence on parenteral nutrition (PN). Teduglutide (TED), a glucagon-like peptide-2 analogue, promotes intestinal adaptation and may reduce PN requirements. Recent real-world data suggest that baseline nutritional status influences t

Source
peer_reviewed_research
DOI
10.1016/j.clnu.2026.106702
PubMed
42275987
Open original source
2025Observational human evidence

Reduction of Parenteral Nutrition in Children with Short Bowel Syndrome Treated with Teduglutide: Experience from the Czech Republic.

Content-verified record concerning Teduglutide: "Reduction of Parenteral Nutrition in Children with Short Bowel Syndrome Treated with Teduglutide: Experience from the Czech Republic." Abstract excerpt: Short bowel syndrome (SBS) results from a severe reduction in intestinal absorptive capacity, rendering it insufficient to meet the body's nutritional requirements. Teduglutide represents a novel therapeutic approach for patients with SBS. This study aims to share our experiences and outcomes of Teduglutide treatment in children with SBS, focusing on the development of their anthropometric paramet

Source
peer_reviewed_research
DOI
10.1055/a-2646-0683
PubMed
40744073
Open original source
2022Observational human evidence

Hernia enlargement and pancreatitis in a patient with short bowel syndrome treated with teduglutide.

Content-verified record concerning Teduglutide: "Hernia enlargement and pancreatitis in a patient with short bowel syndrome treated with teduglutide." Abstract excerpt: Introduction: teduglutide (TED) is indicated for the treatment of patients with short-bowel syndrome (SBS) who are dependent on parenteral support. Case report: we report the case of a 60-year-old woman with SBS treated with TED. She had previously undergone multiple surgical resections due to Crohn's disease. Her remnant bowel included only the duodenum and 50-60 centimeters of jejunum. The patie

Source
peer_reviewed_research
DOI
10.20960/nh.03879
PubMed
34903028
Open original source
2020Observational human evidence

Comprehensive nutritional assessment in short bowel syndrome with chronic renal failure on teduglutide therapy: A case report.

Content-verified record concerning Teduglutide: "Comprehensive nutritional assessment in short bowel syndrome with chronic renal failure on teduglutide therapy: A case report." Abstract excerpt: We report the case of a 62-y-old woman with short bowel syndrome (SBS) and chronic renal failure, successfully treated with teduglutide, who underwent comprehensive systematic nutritional assessment including bioelectrical impedance vectorial analysis (BIVA). The patient did not tolerate the attempt of gradual suspension of parenteral nutrition (PN), bumping into the worsening of nutritional statu

Source
peer_reviewed_research
DOI
10.1016/j.nut.2020.110720
PubMed
32088500
Open original source
2023Observational human evidence

Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring.

Content-verified record concerning Teduglutide: "Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring." Abstract excerpt: Teduglutide is a GLP-2 analog indicated for the treatment of short bowel syndrome (SBS) since 2015. Its efficacy in reducing parenteral nutrition (PN) has been shown in patients with SBS. Because teduglutide is a trophic factor, the aim of this study was to assess risk of developing polypoid intestinal lesions during treatment. A retrospective study was conducted in 35 patients with SBS treated wi

Source
peer_reviewed_research
DOI
10.1016/j.ajcnut.2023.02.015
PubMed
37270288
Open original source
2023Observational human evidence

Nutritional management of a patient with chronic intestinal failure and hemodialysis receiving teduglutide: A case report.

Content-verified record concerning Teduglutide: "Nutritional management of a patient with chronic intestinal failure and hemodialysis receiving teduglutide: A case report." Abstract excerpt: We present the case of a 35-y-old woman with short bowel syndrome secondary to extensive intestinal resection with associated chronic kidney disease who was undergoing hemodialysis. This patient required permanent supplementation with intradialytic parenteral nutrition because of a high-output end-jejunostomy. The patient was a candidate for treatment with teduglutide, a glucagon-like peptide 2 an

Source
peer_reviewed_research
DOI
10.1016/j.nut.2023.112137
PubMed
37481817
Open original source
2018Observational human evidence

De Novo Development of Hamartomatous Duodenal Polyps in a Patient With Short Bowel Syndrome During Teduglutide Therapy: A Case Report.

Content-verified record concerning Teduglutide: "De Novo Development of Hamartomatous Duodenal Polyps in a Patient With Short Bowel Syndrome During Teduglutide Therapy: A Case Report." Abstract excerpt: Teduglutide (TG) is approved for the treatment of parenteral nutrition (PN)-dependent adult patients with short bowel syndrome (SBS). Its well-known adverse effect is expedited growth of colon polyps and potential formation of new polyps. Apart from animal studies, de novo development of duodenal polyps in a patient during TG therapy has not been reported in the literature. We report a case of a 7

Source
peer_reviewed_research
DOI
10.1177/0148607117718480
PubMed
28666089
Open original source
2025Observational human evidence

Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide.

Content-verified record concerning Teduglutide: "Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide." Abstract excerpt: d-Lactic acidosis is an uncommon cause of acidosis that occurs in patients with short bowel syndrome (SBS). Reduced intestinal absorption surface leads to carbohydrate malabsorption, fermented by abnormal colonic bacterial flora, resulting in elevated d-lactate levels. It should be suspected in SBS patients who exhibit typical neurological symptoms without other apparent causes, along with metabol

Source
peer_reviewed_research
DOI
10.1016/j.endien.2025.101535
PubMed
40086997
Open original source
2019Observational human evidence

Accelerated Colorectal Polyposis in an Immunosuppressed Patient With a Small Bowel Transplant Treated With Teduglutide: Case Report and Review of Literature.

Content-verified record concerning Teduglutide: "Accelerated Colorectal Polyposis in an Immunosuppressed Patient With a Small Bowel Transplant Treated With Teduglutide: Case Report and Review of Literature." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1016/j.clcc.2019.02.006
PubMed
31176580
Open original source
2025Observational human evidence

Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome.

Content-verified record concerning Teduglutide: "Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome." Abstract excerpt: Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, is indicated to treat short bowel syndrome (SBS) since 2015. It has been shown to reduce parenteral support (PS) in SBS patients, although patients' response is quite heterogeneous. The exact mechanisms of action of GLP-2 on intestinal cells are still poorly understood. The aim of this study was to explore the intestinal action of teduglutide

Source
peer_reviewed_research
DOI
10.1016/j.clnu.2025.05.006
PubMed
40414050
Open original source
2022Observational human evidence

Changes in Parenteral Nutrition Requirements and BMI in Patients with Parenteral Nutrition-Dependent Short Bowel Syndrome after Stopping Teduglutide-9 Years of Follow-Up.

Content-verified record concerning Teduglutide: "Changes in Parenteral Nutrition Requirements and BMI in Patients with Parenteral Nutrition-Dependent Short Bowel Syndrome after Stopping Teduglutide-9 Years of Follow-Up." Abstract excerpt: Teduglutide (TED) is widely used in patients with short-bowel-syndrome-associated intestinal failure (SBS-IF) to enhance intestinal adaptation and reduce the need for parenteral support (PS). There are limited data on the effects of discontinuing TED. In this study, we describe the changes in parenteral nutrition (PN) requirements and body mass index (BMI) in a 9-year follow-up of patients receivi

Source
peer_reviewed_research
DOI
10.3390/nu14081634
PubMed
35458196
Open original source
2021Observational human evidence

Intestinal iatrogenic hyperadaptation in patients with short bowel syndrome and Crohn's disease: Is this an indication for mandatory lifelong injections of teduglutide?

Content-verified record concerning Teduglutide: "Intestinal iatrogenic hyperadaptation in patients with short bowel syndrome and Crohn's disease: Is this an indication for mandatory lifelong injections of teduglutide?" Abstract excerpt: Short bowel syndrome with chronic intestinal failure (SBS-CIF) is a rare disease leading to a markedly decreased absorption of fluids and nutrients. Intestinal adaptation in patients with SBS-CIF who are treated with home parenteral nutrition is a natural repair process activated by increased secretions of glucagon-like peptide-2, inducing intestinal trophism, nutrient transport, and lowering gast

Source
peer_reviewed_research
DOI
10.1016/j.nut.2021.111396
PubMed
34399400
Open original source
2023Animal research

Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure-A Nested Matched Pair Real-World Study.

Content-verified record concerning Teduglutide: "Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure-A Nested Matched Pair Real-World Study." Abstract excerpt: Quality of life (QoL) data of chronic intestinal failure (cIF) patients treated with the GLP-2 analogue teduglutide are scarce. This study aims to analyze QoL changes over time in teduglutide-treated patients and compare the results to a matched non-treated cIF control group in a real-world setting. QoL data (SF-36 and SBS-QoL TM ) were obtained from adult cIF patients being treated with tedugluti

Source
peer_reviewed_research
DOI
10.3390/nu15081949
PubMed
37111167
Open original source
2021Animal research

Expression, purification and molecular dynamics simulation of extracellular domain of glucagon-like peptide-2 receptor linked to teduglutide.

Content-verified record concerning Teduglutide: "Expression, purification and molecular dynamics simulation of extracellular domain of glucagon-like peptide-2 receptor linked to teduglutide." Abstract excerpt: Teduglutide is the only drug approved for long-term treatment of short bowel syndrome (SBS). This drug exerts its pharmacological effects via binding to the GLP-2 receptors (ECD-GLP2R) located in intestinal tissue. The three dimensional (3D) structure of ECD-GLP2R hasn't been determined yet and hence its mode of interaction with agonists/antagonists is not clear. Therefore, it would be of great im

Source
peer_reviewed_research
DOI
10.1016/j.ijbiomac.2021.06.141
PubMed
34174312
Open original source
2011Animal research

Effect of different doses of GLP-2 (Teduglutide) on acute esophageal lesion due to acid-pepsin perfusion in male rats.

Content-verified record concerning Teduglutide: "Effect of different doses of GLP-2 (Teduglutide) on acute esophageal lesion due to acid-pepsin perfusion in male rats." Abstract excerpt: Gastro-esophageal reflux currently is widespread disorders with dangerous complications. GLP-2 is a peptide that has trophic and anti-inflammatory effects on gastrointestinal mucosa. The aim of this study was to evaluate the protective role of GLP-2 in esophageal mucosa lesion due to perfusion acid-pepsin. Thirty-six male rats were used in this study and divided into six groups. They were control,

Source
peer_reviewed_research
DOI
10.1016/j.peptides.2011.09.004
PubMed
21930171
Open original source
2017Animal research

Intestinal inflammatory and redox responses to the perioperative administration of teduglutide in rats.

Content-verified record concerning Teduglutide: "Intestinal inflammatory and redox responses to the perioperative administration of teduglutide in rats." Abstract excerpt: To investigate the inflammatory and redox responses to teduglutide on an animal model of laparotomy and intestinal anastomosis. Wistar rats (n=62) were allocated into four groups: "Ileal Resection and Anastomosis" vs. "Laparotomy", each one split into "Postoperative Teduglutide Administration" vs. "No Treatment"; and euthanized at the third or the seventh day. Ileal and blood samples were recovere

Source
peer_reviewed_research
DOI
10.1590/s0102-865020170080000007
PubMed
28902941
Open original source
2023Animal research

Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome.

Content-verified record concerning Teduglutide: "Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome." Abstract excerpt: The human intestinal tract reacts to extensive resection with spontaneous intestinal adaptation. We analyzed whether gene expression analyses or intestinal permeability (IP) testing could provide biomarkers to describe regulation mechanisms in the intestinal barrier in short bowel syndrome (SBS) patients during adaptive response or treatment with the glucagon-like peptide-2 analog teduglutide. Rel

Source
peer_reviewed_research
DOI
10.3390/nu15194220
PubMed
37836505
Open original source
2022Animal research

Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP).

Content-verified record concerning Teduglutide: "Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP)." Abstract excerpt: In recent years, the spectrum of possible treatments for Intestinal Failure (IF)-Short Bowel Syndrome (SBS) has been enriched by the implementation of GLP-2 analogues. In Italy, teduglutide (Ted), an analogue of GLP-2, was approved in January 2021 by the Italian Regulatory Agency for Drugs (AIFA) for IF-SBS patients ≥1 year old. According to the Agency indications, Ted can now be prescribed

Source
peer_reviewed_research
DOI
10.1016/j.dld.2022.04.028
PubMed
35654733
Open original source
2020Animal research

Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency.

Content-verified record concerning Teduglutide: "Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency." Abstract excerpt: In short bowel syndrome, epithelial surface loss results in impaired nutrient absorption and may lead to intestinal insufficiency or intestinal failure. Nucleotide oligomerization domain 2 (Nod2) dysfunction predisposes to the development of intestinal failure after intestinal resection and is associated with intestinal barrier defects. Epithelial barrier function is crucial for intestinal absorpt

Source
peer_reviewed_research
DOI
10.1007/s10620-020-06140-6
PubMed
32072437
Open original source
2023Animal research

[Expert recommendations on the use of teduglutide in pediatric patients with short bowel syndrome].

Content-verified record concerning Teduglutide: "[Expert recommendations on the use of teduglutide in pediatric patients with short bowel syndrome]." Abstract excerpt: Short bowel syndrome is a low-incidence disorder among pediatric patients, but it is associated with high morbidity and mortality rates. Management of these patients by an interdisciplinary team of experts focused on intestinal rehabilitation improves short- and long-term outcomes. Available resources for treatment include teduglutide, a glucagon-like peptide type 2 (GLP-2) analog made by recombin

Source
peer_reviewed_research
PubMed
36774605
Open original source
2018Animal research

Tissular growth factors profile after teduglutide administration on an animal model of intestinal anastomosis.

Content-verified record concerning Teduglutide: "Tissular growth factors profile after teduglutide administration on an animal model of intestinal anastomosis." Abstract excerpt: Teduglutide is an enterotrophic analogue of glucagon-like peptide-2, with an indirect and poorly understood mechanism of action, approved for the rehabilitation of short-bowel syndrome. This study aims to analyze the response of tissue growth factors to surgical injury and teduglutide administration on an animal model of intestinal anastomosis. Wistar rats (n = 59) were distributed into four group

Source
peer_reviewed_research
DOI
10.20960/nh.1326
PubMed
29565168
Open original source
2024Animal research

Orally Delivered Stimulus-Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease.

Content-verified record concerning Teduglutide: "Orally Delivered Stimulus-Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease." Abstract excerpt: Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition affecting the gastrointestinal tract (GIT). Glucagon-like peptide-2 (GLP-2) analogs possess high potential in the treatment of IBD by enhancing intestinal repair and attenuating inflammation. Due to the enzymatic degradation and poor intestinal absorption, GLP-2 analogs are administered parenterally, which leads to poor patient c

Source
peer_reviewed_research
DOI
10.1002/smll.202402502
PubMed
39007246
Open original source
2018Animal research

Teduglutide-induced stem cell function in intestinal repair.

Content-verified record concerning Teduglutide: "Teduglutide-induced stem cell function in intestinal repair." Abstract excerpt: Malabsorption is a major and common clinical characteristics of short bowel syndrome (SBS) and inflammatory bowel diseases (IBD). Traditional treatment opportunities have focused on decreasing malabsorptive losses via dietary modifications and antisecretory/antidiarrheal agents. However, novel therapeutic modalities aim to enhance the absorptive capacity of the residual bowel by the administration

Source
peer_reviewed_research
DOI
10.1080/08941939.2017.1300715
PubMed
28590166
Open original source
2017Animal research

Teduglutide effects on gene regulation of fibrogenesis on an animal model of intestinal anastomosis.

Content-verified record concerning Teduglutide: "Teduglutide effects on gene regulation of fibrogenesis on an animal model of intestinal anastomosis." Abstract excerpt: Teduglutide is an enterotrophic analog of glucagon-like peptide 2 approved for the rehabilitation of short-bowel syndrome. This study aims to analyze the effects of teduglutide administration on the gene regulation of fibrogenesis during the intestinal anastomotic healing on an animal model. Wistar rats (n = 62) were assigned into four groups: "Ileal Resection and Anastomosis" or "Laparo

Source
peer_reviewed_research
DOI
10.1016/j.jss.2017.04.022
PubMed
28807218
Open original source
2013Animal research

Teduglutide for the treatment of short bowel syndrome.

Content-verified record concerning Teduglutide: "Teduglutide for the treatment of short bowel syndrome." Abstract excerpt: Glucagon-like peptide 2 (GLP-2) decreases gastric and intestinal motility, reduces gastric secretions, promotes intestinal growth and improves post-resection structural and functional adaptation in short bowel syndrome (SBS). Teduglutide, an analogue of GLP-2, has a prolonged half-life and provides intestinotrophic effects with once-daily subcutaneous injection in patients with SBS. This monograph

Source
peer_reviewed_research
DOI
10.1358/dot.2013.49.10.2017025
PubMed
24191254
Open original source
2012Animal research

Teduglutide, a glucagon-like peptide 2 analogue: a novel protective agent with anti-apoptotic and anti-oxidant properties in mice with lung injury.

Content-verified record concerning Teduglutide: "Teduglutide, a glucagon-like peptide 2 analogue: a novel protective agent with anti-apoptotic and anti-oxidant properties in mice with lung injury." Abstract excerpt: Teduglutide is a long-acting synthetic analogue of human glucagon-like peptide-2 (GLP-2). GLP-2 regulates cell proliferation and apoptosis as well as normal physiology in the gastrointestinal tract. In the present study, possible cytoprotective and reparative effects of teduglutide were analyzed on a mouse model with lung injury induced by tumor necrosis factor-alpha (TNF-α) and actinomycin

Source
peer_reviewed_research
DOI
10.1016/j.peptides.2012.09.030
PubMed
23059393
Open original source
2004Animal research

Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage.

Content-verified record concerning Teduglutide: "Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage." Abstract excerpt: Glucagon-like peptide-2 and its dipeptidyl peptidase (DP-IV) resistant analogue teduglutide are trophic for the gastrointestinal epithelium. Exposure increases villus height and crypt size and results in increased overall intestinal weight. As these effects may be mediated through stimulation of the stem cell compartment, they may promote intestinal healing and act as potential anti-mucositis agen

Source
peer_reviewed_research
DOI
10.1111/j.1365-2184.2004.00320.x
PubMed
15548172
Open original source
2017Animal research

Teduglutide for treatment of adult patients with short bowel syndrome.

Content-verified record concerning Teduglutide: "Teduglutide for treatment of adult patients with short bowel syndrome." Abstract excerpt: The European Society for Clinical Nutrition has published recommendations on the 'definition and classification of intestinal failure (IF)'. Two criteria must be present: a 'decreased absorption of macronutrients and/or water and electrolytes due to a loss of gut function' and the 'need for parenteral support'. Home parenteral support (HPS) is the primary treatment for chronic IF but is associated

Source
peer_reviewed_research
DOI
10.1080/14712598.2017.1304912
PubMed
28293969
Open original source
2024Animal research

Cost-Effectiveness of Teduglutide for Pediatric Patients with Short Bowel Syndrome in Japan, Including Caregiver Burden.

Content-verified record concerning Teduglutide: "Cost-Effectiveness of Teduglutide for Pediatric Patients with Short Bowel Syndrome in Japan, Including Caregiver Burden." Abstract excerpt: Short bowel syndrome (SBS) is associated with a significant mental and physical burden for patients and caregivers. Standard of care (SOC) for SBS includes parenteral support (PS) to optimize intestinal function. Teduglutide, a recombinant human glucagon-like peptide 2 analogue, reduces the need for PS in patients with SBS. In this study, we assessed the cost-effectiveness of teduglutide in p

Source
peer_reviewed_research
DOI
10.1007/s12325-024-02995-7
PubMed
39412630
Open original source
2022Animal research

Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers.

Content-verified record concerning Teduglutide: "Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers." Abstract excerpt: Teduglutide, the active ingredient of the medicine Revestive® (5 mg), is a recombinant therapeutic peptide that mimics the effects of the endogenous glucagon-like peptide 2 (GLP-2). It stimulates intestinal growth, adaptation and function in patients with Short Bowel Syndrome who are dependent on parenteral nutrition. The Summary of Product Characteristics recommends immediate use of the

Source
peer_reviewed_research
DOI
10.1016/j.jpba.2022.115064
PubMed
36152491
Open original source
2026Animal research

Development of a consensus parenteral solution weaning algorithm for children with short-bowel syndrome associated intestinal failure responding to teduglutide therapy.

Content-verified record concerning Teduglutide: "Development of a consensus parenteral solution weaning algorithm for children with short-bowel syndrome associated intestinal failure responding to teduglutide therapy." Abstract excerpt: Teduglutide is a glucagon-like peptide 2 analogue with demonstrated efficacy in reducing parenteral solution (PS) requirements to facilitate enteral autonomy in children with short bowel syndrome-associated intestinal failure (SBS-IF). There is currently no clear consensus on how to wean PS and monitor children once treatment is commenced, with variable regimens utilised in published paediatric an

Source
peer_reviewed_research
DOI
10.1136/archdischild-2025-328743
PubMed
41184096
Open original source
2026Animal research

Efficacy and safety of teduglutide in children with short bowel syndrome: a narrative review.

Content-verified record concerning Teduglutide: "Efficacy and safety of teduglutide in children with short bowel syndrome: a narrative review." Abstract excerpt: Short bowel syndrome (SBS) in children often requires long-term parenteral support (PS), predisposing to liver disease, catheter-related complications, and reduced quality of life. Teduglutide has shown promise in enhancing intestinal adaptation and reducing PS dependence in children with SBS. A narrative review was conducted in PubMed, CNKI, and WANFANG databases to identify studies published fro

Source
peer_reviewed_research
DOI
10.1007/s00383-026-06474-8
PubMed
42622692
Open original source
2021Animal research

Cost-effectiveness of teduglutide in pediatric patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.

Content-verified record concerning Teduglutide: "Cost-effectiveness of teduglutide in pediatric patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria." Abstract excerpt: Teduglutide use in pediatric patients with short bowel syndrome can aid in the achievement of enteral autonomy, but with a price of >$400,000 per y. The current study evaluated the cost-effectiveness of using teduglutide in conjunction with offering intestinal transplantation in US pediatric patients with short bowel syndrome. A Markov model was used to evaluate the costs (in US dollars) and ef

Source
peer_reviewed_research
DOI
10.1093/ajcn/nqaa278
PubMed
33021637
Open original source
2020Animal research

Translation of Evidence Into Practice With Teduglutide in the Management of Adults With Intestinal Failure due to Short-Bowel Syndrome: A Review of Recent Literature.

Content-verified record concerning Teduglutide: "Translation of Evidence Into Practice With Teduglutide in the Management of Adults With Intestinal Failure due to Short-Bowel Syndrome: A Review of Recent Literature." Abstract excerpt: Chronic intestinal failure (CIF) due to short-bowel syndrome (SBS) is characterized by failure to achieve optimal intestinal adaptation required to maintain oral/enteral autonomy. The conventional management strategy relies heavily on home parenteral support (PS; parenteral nutrition and/or intravenous fluids). Teduglutide, an analog of the hormone glucagon-like peptide-2, facilitates intestinal a

Source
peer_reviewed_research
DOI
10.1002/jpen.1757
PubMed
31802516
Open original source
2023Animal research

Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive®) structural description and stress testing.

Content-verified record concerning Teduglutide: "Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive®) structural description and stress testing." Abstract excerpt: Teduglutide (Revestive®) is a glucagon-like peptide-2 analogue used for the treatment of short bowel syndrome, a rare life-threatening condition in which the amount of functional gut is too short to enable proper absorption of nutrients and fluids. During handling prior to administration to the patient in hospital, it is possible that peptide-based medicines may be exposed to environmental st

Source
peer_reviewed_research
DOI
10.1016/j.ejpb.2023.01.001
PubMed
36669672
Open original source
2025Animal research

Encapsulation of hydrophobically ion-paired teduglutide in nanoemulsions: Effect of anionic counterions.

Content-verified record concerning Teduglutide: "Encapsulation of hydrophobically ion-paired teduglutide in nanoemulsions: Effect of anionic counterions." Abstract excerpt: This study presents a novel method for encapsulating the bioactive peptide teduglutide to enhance its oral bioavailability using O/W nanoemulsion (NE). Recombinant teduglutide (rTGT), produced in E. coli with 93 % purity, was hydrophobically modified through ion-pairing with phytic acid (PA) and sodium dodecyl sulfate (SDS). This approach increased encapsulation efficiency from 48.5 % to

Source
peer_reviewed_research
DOI
10.1016/j.foodchem.2025.142774
PubMed
39788016
Open original source
2020Animal research

Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.

Content-verified record concerning Teduglutide: "Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria." Abstract excerpt: Adults with short bowel syndrome have a high mortality and significant morbidity due to unsuccessful attempts at rehabilitation that necessitate chronic use of parenteral nutrition (PN). Teduglutide is a novel therapy that promotes intestinal adaptation to improve rehabilitation but with a price >$400,000/y. The current study evaluated the cost-effectiveness of using teduglutide in US adult pat

Source
peer_reviewed_research
DOI
10.1093/ajcn/nqz269
PubMed
31665212
Open original source
2024Animal research

Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure.

Content-verified record concerning Teduglutide: "Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure." Abstract excerpt: Patients with short bowel syndrome-associated intestinal failure (SBS-IF) require long-term parenteral nutrition and/or intravenous fluids (PN/IV) to maintain fluid or nutritional balance. We report the long-term safety, efficacy, and predictors of response in pediatric patients with SBS-IF receiving teduglutide over 96 weeks. This was a pooled, post hoc analysis of two open-label, long-term exten

Source
peer_reviewed_research
DOI
10.1002/jpn3.12276
PubMed
38873891
Open original source
2018Animal research

Intestinal Epithelial Stem Cells: Distinct Behavior After Surgical Injury and Teduglutide Administration.

Content-verified record concerning Teduglutide: "Intestinal Epithelial Stem Cells: Distinct Behavior After Surgical Injury and Teduglutide Administration." Abstract excerpt: Previous studies suggest that intestinal epithelial stem cells (IESC), critical drivers of homeostasis and regeneration, include two subpopulations: crypt-based columnar and "position +4" stem cells, identified by Lgr5 and Bmi1 biomarkers, respectively. Teduglutide is an enterotrophic counterpart of glucagon-like peptide 2. This study aimed to investigate the response of putative IESC to surgical

Source
peer_reviewed_research
DOI
10.1080/08941939.2017.1294217
PubMed
28362133
Open original source
2021Animal research

Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome.

Content-verified record concerning Teduglutide: "Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome." Abstract excerpt: Teduglutide is a recombinant analog of human glucagon-like peptide-2 that regulates the functional and structural integrity of the cells lining the gastrointestinal tract. Teduglutide is approved for the treatment of patients with short bowel syndrome (SBS) who are dependent on parenteral support (PS). Population pharmacokinetic (PK) and exposure-response analyses were performed to support teduglu

Source
peer_reviewed_research
DOI
10.1111/cts.13117
PubMed
34402197
Open original source
2023Animal research

Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome.

Content-verified record concerning Teduglutide: "Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome." Abstract excerpt: A growing proportion of children with short bowel syndrome (SBS) remain dependent on long-term parenteral nutrition (PN). Teduglutide offers the potential for more children to decrease PN support and achieve enteral autonomy (EA), but at a significant expense. This study aims to assess the incremental costs of teduglutide plus standard of care compared to standard of care alone in weaning PN suppo

Source
peer_reviewed_research
DOI
10.1016/j.clnu.2023.10.001
PubMed
37862822
Open original source
2025Animal research

Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries.

Content-verified record concerning Teduglutide: "Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries." Abstract excerpt: This study aimed to explore the lived experiences and coping strategies of patients with short bowel syndrome (SBS) prescribed teduglutide and weaning off home parenteral nutrition (HPN), and to compare the quality of life (QOL) of these patients to patients with SBS but not prescribed teduglutide. A qualitative study was conducted, with patients recruited from a specialist HPN clinic. Participant

Source
peer_reviewed_research
DOI
10.1136/bmjgast-2025-001818
PubMed
40764045
Open original source
2022Animal research

The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience.

Content-verified record concerning Teduglutide: "The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience." Abstract excerpt: The glucagon-like peptide-2 analog Teduglutide has been shown to enhance intestinal absorption and decrease parenteral nutrition (PN) requirements in short bowel syndrome (SBS). As data in children is limited, we evaluated nationwide real-life experience and treatment outcome in children with SBS. Longitudinal data of children treated with Teduglutide for ≥3 months was collected. Data inclu

Source
peer_reviewed_research
DOI
10.1097/mpg.0000000000003541
PubMed
35730756
Open original source
2010Animal research

Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease.

Content-verified record concerning Teduglutide: "Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease." Abstract excerpt: Teduglutide is a GLP-2 analog currently evaluated for the treatment of short bowel syndrome, Crohn's disease, and other gastrointestinal disorders. The population pharmacokinetics (PK) of teduglutide were assessed following daily subcutaneous (SC) administrations of 2.5 to 80 mg doses in a total of 256 patients. A 1-compartment model with a site-specific rate constant of absorption in the abdomen,

Source
peer_reviewed_research
DOI
10.1177/0091270009342252
PubMed
19773525
Open original source
2023Animal research

[Review of real-life teduglutide experience].

Content-verified record concerning Teduglutide: "[Review of real-life teduglutide experience]." Abstract excerpt: Background: teduglutide is an agonist of glucagon-related peptide (aGLP2) effective as a treatment for patients with short bowel syndrome (SBS), an entity that affects quality of life, usually requires home parenteral nutrition (HPN) and generates significant health costs. The objective of the present narrative review was to assess the real-life experience reported with teduglutide. Methods and re

Source
peer_reviewed_research
DOI
10.20960/nh.04646
PubMed
37409717
Open original source
2022Animal research

Method for identification and quantification of intact teduglutide peptide using (RP)UHPLC-UV-(HESI/ORBITRAP)MS.

Content-verified record concerning Teduglutide: "Method for identification and quantification of intact teduglutide peptide using (RP)UHPLC-UV-(HESI/ORBITRAP)MS." Abstract excerpt: Teduglutide (Revestive®, 10 mg mL -1 ) is a recombinant human glucagon-like peptide 2 analogue, used in the treatment of short bowel syndrome, a serious and highly disabling condition which results from either too small a length of intestine or loss of critical intestinal function. The determination of therapeutic compounds of protein-nature is always challenging due to their complex structur

Source
peer_reviewed_research
DOI
10.1039/d2ay01254e
PubMed
36263764
Open original source
2014Animal research

Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.

Content-verified record concerning Teduglutide: "Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome." Abstract excerpt: Neonatal short bowel syndrome following massive gut resection is associated with malabsorption of nutrients. The intestinotrophic factor glucagon-like peptide 2 (GLP-2) improves gut function in adult patients with short bowel syndrome, but its effect in pediatric patients remains unknown. Our objective was to test the efficacy of the long-acting synthetic human GLP-2 analogue, teduglutide (ALX-060

Source
peer_reviewed_research
DOI
10.1097/mpg.0000000000000295
PubMed
24399211
Open original source
2027Animal research

Development of Teduglutide purity certified reference material (GBW09342) through amino acid-based isotope dilution mass spectrometry and sulfur-based isotope dilution inductively coupled plasma mass spectrometry.

Content-verified record concerning Teduglutide: "Development of Teduglutide purity certified reference material (GBW09342) through amino acid-based isotope dilution mass spectrometry and sulfur-based isotope dilution inductively coupled plasma mass spectrometry." Abstract excerpt: As a severe intestinal disorder, short bowel syndrome (SBS) has become the leading cause of chronic intestinal failure worldwide. Teduglutide, a 33-amino-acid glucagon-like peptide-2 (GLP-2) analog, offers a novel therapeutic option for individuals suffering from SBS. In this study, Teduglutide purity certified reference material (CRM) with certified value and expanded uncertainty of (85.0%&#x202f

Source
peer_reviewed_research
DOI
10.1016/j.talanta.2026.130223
PubMed
42385596
Open original source
2013Animal research

Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells.

Content-verified record concerning Teduglutide: "Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells." Abstract excerpt: Short bowel syndrome occurs when a shortened intestine cannot absorb sufficient nutrients or fluids. Teduglutide is a recombinant analogue of human glucagonlike peptide 2 that reduces dependence on parenteral nutrition in patients with short bowel syndrome by promoting enterocytic proliferation, increasing the absorptive surface area. However, enterocyte function depends not only on the number of

Source
peer_reviewed_research
DOI
10.1001/jamasurg.2013.3731
PubMed
24068167
Open original source
2017Animal research

The Polish Intestinal Failure Centres' consensus on the use of teduglutide for the treatment of short bowel syndrome.

Content-verified record concerning Teduglutide: "The Polish Intestinal Failure Centres' consensus on the use of teduglutide for the treatment of short bowel syndrome." Abstract excerpt: Teduglutide is an active, glucagon-like peptide (GLP)-2 analog with proven clinical efficacy regarding intestinal adaptation in patients with short bowel syndrome (SBS). There are two factors that preclude its reimbursement, and thereby, its availability: its cost (reaching ∼$300,000/y)-which significantly exceeds the cost of home parenteral nutrition (HPN) in most countries-and the lack of

Source
peer_reviewed_research
DOI
10.1016/j.nut.2016.12.022
PubMed
28526379
Open original source
2020Animal research

The Glucagon-Like Peptide 2 Analog Teduglutide Reversibly Associates to Form Pentamers.

Content-verified record concerning Teduglutide: "The Glucagon-Like Peptide 2 Analog Teduglutide Reversibly Associates to Form Pentamers." Abstract excerpt: Glucagon-like peptide 1 and 2 and their analog peptide therapeutics are known to reversibly associate to form oligomers. Here we report the association properties of the glucagon-like peptide 2 analog teduglutide at concentrations up to ∼15 mg/mL. Both sedimentation equilibrium (SE-AUC) and sedimentation velocity (SV-AUC) show that teduglutide dissociates completely to monomers below 0.1 mg

Source
peer_reviewed_research
DOI
10.1016/j.xphs.2019.06.028
PubMed
31306652
Open original source
2017Laboratory research

Teduglutide: A Review in Short Bowel Syndrome.

Review of teduglutide in short bowel syndrome; underlying studies require direct appraisal.

Source
peer_reviewed_research
DOI
10.1007/s40265-017-0703-7
PubMed
28194723
Open original source
2023Insufficient evidence

The indications and results of the use of teduglutide in patients with short bowel.

Content-verified record concerning Teduglutide: "The indications and results of the use of teduglutide in patients with short bowel." Abstract excerpt: Short bowel syndrome (SBS) is a rare condition defined as a reduced residual functional small intestinal length to less than 200 cm often resulting from extensive intestinal resection, and can lead to chronic intestinal failure (CIF). Patients with SBS-CIF are unable to absorb sufficient nutrients or fluids to maintain metabolic homeostasis through oral or enteral intake and require long-te

Source
peer_reviewed_research
DOI
10.1097/mco.0000000000000964
PubMed
37421385
Open original source
2014Insufficient evidence

Vortioxetine hydrobromide, crofelemer, and teduglutide.

Content-verified record concerning Teduglutide: "Vortioxetine hydrobromide, crofelemer, and teduglutide." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1331/japha.2014.14506
PubMed
24407747
Open original source
Insufficient evidence

Successful treatment with teduglutide for an adolescent with cerebral palsy accompanied by short bowel syndrome.

Source reference associated with Teduglutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1111/ped.15894
PubMed
40019443
Open original source
2015Insufficient evidence

[Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) for teduglutide-benefit assessment according to § 35a SGB V the G-BA].

Content-verified record concerning Teduglutide: "[Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) for teduglutide-benefit assessment according to § 35a SGB V the G-BA]." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1055/s-0034-1397528
PubMed
25821868
Open original source
2013Insufficient evidence

The long road to a new short-bowel therapy: teduglutide for clinical use.

Content-verified record concerning Teduglutide: "The long road to a new short-bowel therapy: teduglutide for clinical use." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1016/j.cgh.2013.03.030
PubMed
23591284
Open original source
2016Insufficient evidence

Response to "Teduglutide and Intestinal Permeability in Short Bowel Syndrome".

Content-verified record concerning Teduglutide: "Response to "Teduglutide and Intestinal Permeability in Short Bowel Syndrome"." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1177/0148607116637848
PubMed
27875269
Open original source
2016Insufficient evidence

A Patient With Parenteral Nutrition-Dependent Short Bowel Syndrome and Cardiovascular Disease With 4-Year Exposure to Teduglutide.

Content-verified record concerning Teduglutide: "A Patient With Parenteral Nutrition-Dependent Short Bowel Syndrome and Cardiovascular Disease With 4-Year Exposure to Teduglutide." Abstract excerpt: Clinical trials of the glucagon-like peptide 2 analogue teduglutide resulted in approval of the drug by the Food and Drug Administration in 2012 as a treatment for parenteral nutrition-dependent short bowel syndrome in adults. This report presents the case study of a man with short bowel syndrome caused by portal vein thrombosis who had 4 years exposure to the drug at the time of his death due to

Source
peer_reviewed_research
DOI
10.1177/0148607114566466
PubMed
25567782
Open original source
2026Insufficient evidence

Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study.

Content-verified record concerning Teduglutide: "Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study." Abstract excerpt: Patients with short bowel syndrome (SBS)-associated intestinal failure (SBS-IF) are dependent on parenteral support (PS). In Japan, teduglutide is the only GLP-2 analog medicine indicated for these patients. There are limited data for pediatric patients, especially those with a low body weight. This study evaluated the safety and efficacy of teduglutide in Japanese pediatric patients with SBS-IF (

Source
peer_reviewed_research
DOI
10.1111/ped.70301
PubMed
41454663
Open original source
2024Insufficient evidence

Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis.

Content-verified record concerning Teduglutide: "Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis." Abstract excerpt: Chronic hepatic complications are common in patients with short bowel syndrome-associated intestinal failure (SBS-IF). Teduglutide, a glucagon-like peptide-2 analogue, demonstrated efficacy in reducing parenteral nutrition and/or intravenous fluid dependence among patients with SBS-IF in phase 3 clinical studies. This was a post hoc analysis of pooled data from two separate randomized, double-blin

Source
peer_reviewed_research
DOI
10.1002/ncp.11139
PubMed
38491966
Open original source
2022Insufficient evidence

Teduglutide in short bowel syndrome patients: A way back to normal life?

Content-verified record concerning Teduglutide: "Teduglutide in short bowel syndrome patients: A way back to normal life?" Abstract excerpt: The glucagon-like peptide 2 analogue teduglutide is an effective drug for the treatment of short bowel syndrome patients with intestinal failure (SBS-IF). This intestinotrophic peptide improves intestinal capacity for fluid and nutrient absorption through induction of mucosal growth and reduction of gastrointestinal motility. Clinical trials demonstrated the efficacy of teduglutide in reducing the

Source
peer_reviewed_research
DOI
10.1002/jpen.2272
PubMed
34614239
Open original source
Insufficient evidence

Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina.

Source reference associated with Teduglutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.4292/wjgpt.v16.i4.110642
PubMed
41378076
Open original source
2020Insufficient evidence

Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials.

Content-verified record concerning Teduglutide: "Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials." Abstract excerpt: In multiple clinical studies, teduglutide reduced parenteral support (PS) with a consistent safety profile in adults with short bowel syndrome-associated intestinal failure (SBS-IF). The objective of this study was to assess adverse events (AEs) from a pooled data set. Safety data from four prospective clinical trials of teduglutide in patients with SBS-IF were assimilated. AEs were evaluated in p

Source
peer_reviewed_research
DOI
10.1177/1756284820905766
PubMed
32341691
Open original source
2018Insufficient evidence

Teduglutide for the treatment of short bowel syndrome - a safety evaluation.

Content-verified record concerning Teduglutide: "Teduglutide for the treatment of short bowel syndrome - a safety evaluation." Abstract excerpt: Teduglutide is an analog of glucagon-like peptide 2 (GLP-2) which is approved for the treatment of patients with short bowel syndrome (SBS) who are dependent on parenteral support. Areas covered: Short bowel syndrome is a rare condition that can result from extensive resection of small bowel, congenital abnormalities, or inflammatory conditions that leads to poor nutrient processing capacity of th

Source
peer_reviewed_research
DOI
10.1080/14740338.2018.1483332
PubMed
29848084
Open original source
2017Insufficient evidence

Teduglutide-Stimulated Intestinal Adaptation Is Complemented and Synergistically Enhanced by Partial Enteral Nutrition in a Neonatal Piglet Model of Short Bowel Syndrome.

Content-verified record concerning Teduglutide: "Teduglutide-Stimulated Intestinal Adaptation Is Complemented and Synergistically Enhanced by Partial Enteral Nutrition in a Neonatal Piglet Model of Short Bowel Syndrome." Abstract excerpt: Teduglutide, a glucagon-like peptide-2 (GLP-2) analogue, is available for long-term use by parenteral nutrition (PN)-dependent adults to promote intestinal adaptation but is not approved for use in pediatric patients. The objective of this study was to assess teduglutide-stimulated induced intestinal adaptation, potential synergies with partial enteral nutrition (PEN), and distinct temporal marker

Source
peer_reviewed_research
DOI
10.1177/0148607115602891
PubMed
26304601
Open original source
2015Insufficient evidence

Teduglutide: a guide to its use in short bowel syndrome.

Content-verified record concerning Teduglutide: "Teduglutide: a guide to its use in short bowel syndrome." Abstract excerpt: Teduglutide (Gattex(®)) is a recombinant analogue of human glucagon-like peptide-2 and is indicated for the treatment of adults with short bowel syndrome (SBS) dependent on parenteral support (PS). In a pivotal, 24-week clinical trial in SBS patients, subcutaneous teduglutide 0.05 mg/kg once daily increased absorption from the remnant intestine as evidenced by significant reductions in PS vol

Source
peer_reviewed_research
DOI
10.1007/s40261-015-0286-6
PubMed
25859983
Open original source
2014Insufficient evidence

Teduglutide for the Treatment of Short Bowel Syndrome.

Content-verified record concerning Teduglutide: "Teduglutide for the Treatment of Short Bowel Syndrome." Abstract excerpt: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of the newly approved drug, teduglutide, for the treatment of short bowel syndrome (SBS). Literature was retrieved through PubMed (1966-March 2014) using the search term teduglutide. The authors applied the filters Humans and English language, resulting in 47 publications. The authors reviewed the 47 citations to extract t

Source
peer_reviewed_research
DOI
10.1177/1060028014537468
PubMed
24871569
Open original source
2013Insufficient evidence

Teduglutide: a review of its use in the treatment of patients with short bowel syndrome.

Content-verified record concerning Teduglutide: "Teduglutide: a review of its use in the treatment of patients with short bowel syndrome." Abstract excerpt: The recombinant analogue of human glucagon-like peptide-2 (GLP-2) teduglutide (Gattex(®), Revestive(®)) is a novel therapy for short bowel syndrome (SBS). GLP-2 is a naturally occurring hormone that regulates the growth, proliferation and maintenance of cells lining the gastrointestinal tract. Subcutaneous teduglutide is the first long-term medical therapy approved for the treatment of a

Source
peer_reviewed_research
DOI
10.1007/s40265-013-0070-y
PubMed
23729002
Open original source
2012Insufficient evidence

Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.

Content-verified record concerning Teduglutide: "Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure." Abstract excerpt: Teduglutide, a glucagon-like peptide 2 analogue, might restore intestinal structural and functional integrity by promoting growth of the mucosa and reducing gastric emptying and secretion. These factors could increase fluid and nutrient absorption in patients with short bowel syndrome with intestinal failure (SBS-IF). We performed a prospective study to determine whether teduglutide reduces parent

Source
peer_reviewed_research
DOI
10.1053/j.gastro.2012.09.007
PubMed
22982184
Open original source
2010Insufficient evidence

Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.

Content-verified record concerning Teduglutide: "Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease." Abstract excerpt: Teduglutide, an analog of glucagon-like peptide-2 (GLP-2), is associated with trophic effects on gut mucosa. Its role in the treatment of active Crohn's disease (CD) was assessed in a pilot, randomized, placebo-controlled, double-blinded, dose-ranging study. Subjects with moderate-to-severe CD were randomized 1:1:1:1 to placebo or 1 of 3 doses of teduglutide (0.05, 0.10, or 0.20 mg/kg daily) deliv

Source
peer_reviewed_research
DOI
10.1002/ibd.21117
PubMed
19821509
Open original source
2010Insufficient evidence

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Content-verified record concerning Teduglutide: "Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome." Abstract excerpt: Glucagon-like peptide-2 (GLP-2) is a potent intestinotrophic growth factor with therapeutic potential for the prevention or treatment of an expanding number of gastrointestinal diseases, including short bowel syndrome (SBS). Teduglutide, being developed by NPS Allelix and licensee Nycomed, is a protease-resistant analog of GLP-2 for the potential treatment of gastrointestinal disease. Teduglutide

Source
peer_reviewed_research
PubMed
21154171
Open original source
2006Insufficient evidence

Teduglutide for the treatment of short bowel syndrome.

Content-verified record concerning Teduglutide: "Teduglutide for the treatment of short bowel syndrome." Abstract excerpt: To summarize the pharmacology, development, and clinical application of teduglutide (ALX-0600), a glucagon-like peptide-2 (GLP-2) analog for the treatment of short bowel syndrome (SBS). Clinical literature, including both primary sources and review articles, was accessed through a search of the MEDLINE databases (1980-March 2006). Key search terms included teduglutide, ALX-0600, glucagon-like pept

Source
peer_reviewed_research
DOI
10.1345/aph.1g419
PubMed
16705029
Open original source
2005Insufficient evidence

Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.

Content-verified record concerning Teduglutide: "Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients." Abstract excerpt: Glucagon-like peptide 2 (GLP-2) may improve intestinal absorption in short bowel syndrome (SBS) patients with an end jejunostomy. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant GLP-2 analogue, prolongs the intestinotrophic properties of GLP-2 in animal models. The safety and effect of teduglutide were investigated in SBS patients with and without a colon in continuity. Teduglutide was

Source
peer_reviewed_research
DOI
10.1136/gut.2004.061440
PubMed
16099790
Open original source
2013Insufficient evidence

Increased intestinal absorption in the era of teduglutide and its impact on management strategies in patients with short bowel syndrome-associated intestinal failure.

Content-verified record concerning Teduglutide: "Increased intestinal absorption in the era of teduglutide and its impact on management strategies in patients with short bowel syndrome-associated intestinal failure." Abstract excerpt: Short bowel syndrome-associated intestinal failure (SBS-IF) as a consequence of extensive surgical resection of the gastrointestinal (GI) tract results in a chronic reduction in intestinal absorption. The ensuing malabsorption of a conventional diet with associated diarrhea and weight loss results in a dependency on parenteral nutrition and/or intravenous fluids (PN/IV). A natural compensatory pro

Source
peer_reviewed_research
DOI
10.1177/0148607112472906
PubMed
23343999
Open original source
2008Insufficient evidence

Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects.

Content-verified record concerning Teduglutide: "Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects." Abstract excerpt: Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, is currently being evaluated for the treatment of short-bowel syndrome, Crohn's disease, and other gastrointestinal disorders. The pharmacokinetics, safety, and tolerability of teduglutide in healthy subjects (N = 64) were assessed following daily subcutaneous administrations for 8 days in a double-blinded, randomized, placebo-controlled, asce

Source
peer_reviewed_research
DOI
10.1177/0091270008320605
PubMed
18974283
Open original source
2021Insufficient evidence

Teduglutide for pediatric short bowel syndrome patients.

Content-verified record concerning Teduglutide: "Teduglutide for pediatric short bowel syndrome patients." Abstract excerpt: Introduction : The goal for pediatric short bowel syndrome (SBS) patients is intestinal adaptation. Until recently, the medical management of pediatric SBS has centered on the prevention and treatment of complications in order to allow time for adaptation. Teduglutide, glucagon-like peptide 2 (GLP-2) analog, has recently been approved for use in pediatric SBS patients greater than 1 year of age as

Source
systematic_review_or_meta_analysis
DOI
10.1080/17474124.2021.1913052
PubMed
33798402
Open original source
2016Insufficient evidence

Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review.

Content-verified record concerning Teduglutide: "Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review." Abstract excerpt: Teduglutide (Gattex; NPS Pharma, Bedminster, NJ), a recombinant analogue of human glucagon-like peptide 2 (GLP-2), is the first long-term medical therapy approved for the treatment of adults dependent on parenteral nutrition (PN). To assess the efficacy and safety of teduglutide in reducing PN (parenteral nutrient and/or fluid) requirements in PN-dependent adults. Studies were identified using pre

Source
systematic_review_or_meta_analysis
DOI
10.1177/0148607115582063
PubMed
25883117
Open original source
2006Insufficient evidence

Teduglutide

Content-verified record concerning Teduglutide: "Teduglutide" Abstract excerpt: Because it is a large protein molecule with a molecular weight of 3752 Da, the amount in milk is likely to be very low. Teduglutide is also poorly absorbed orally so absorption by a breastfed infant is unlikely. Two breastfed infants apparently experienced no adverse effects during maternal use of teduglutide, but no long-term data are available. Until more data are available, teduglutide should b

Source
other
PubMed
36701512
Open original source
2016Insufficient evidence

Clinical Management of Patients With Parenteral Nutrition-Dependent Short Bowel Syndrome During Teduglutide Therapy.

Content-verified record concerning Teduglutide: "Clinical Management of Patients With Parenteral Nutrition-Dependent Short Bowel Syndrome During Teduglutide Therapy." Abstract excerpt: Patients with intestinal failure, who are dependent on parenteral nutrition (PN) to supplement their limited absorption of dietary nutrients, are subject to complications associated with long-term PN therapy. Medication therapy that results in improved dietary nutrient absorption may enable these patients to reduce or even become independent from PN therapy and its related complications. The gluca

Source
peer_reviewed_research
DOI
10.1177/0148607115594010
PubMed
26111832
Open original source
2022Insufficient evidence

Use of Teduglutide in Children With Intestinal Failure: A Systematic Review.

Content-verified record concerning Teduglutide: "Use of Teduglutide in Children With Intestinal Failure: A Systematic Review." Abstract excerpt: Short-bowel syndrome (SBS) results from the loss of a significant portion of the small intestine leading to a state of malabsorption. After an intestinal loss, there is a process of adaptation involving the Glucagon-Like Peptide-2 (GLP-2), an enteroendocrine peptide also involved in nutrient absorption. Teduglutide is a recombinant analog of GLP-2 approved in 2016 to treat selected SBS pediatric p

Source
systematic_review_or_meta_analysis
DOI
10.3389/fnut.2022.866518
PubMed
35774551
Open original source
2020Insufficient evidence

Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure.

Content-verified record concerning Teduglutide: "Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure." Abstract excerpt: Teduglutide reduces or eliminates parenteral support (PS) dependency in patients with short bowel syndrome (SBS). Recent post hoc analyses demonstrated that effects are correlated with baseline PS volume. We assessed the SBS-related quality-of-life (QoL) impact of teduglutide, particularly whether improvements are greater among subgroups achieving more PS volume reduction. Using phase 3 trial data

Source
peer_reviewed_research
DOI
10.1002/jpen.1588
PubMed
31006876
Open original source
2016Insufficient evidence

Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome.

Content-verified record concerning Teduglutide: "Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome." Abstract excerpt: In the pivotal 24-week, phase III, placebo-controlled trial, teduglutide significantly reduced parenteral support (PS) requirements in patients with short bowel syndrome (SBS). STEPS-2 was a 2-year, open-label extension of that study designed to evaluate long-term safety and efficacy of teduglutide. Enrolled patients had completed 24 weeks of either teduglutide (TED/TED) or placebo (PBO/TED) in th

Source
peer_reviewed_research
DOI
10.1038/ctg.2015.69
PubMed
26844839
Open original source
Insufficient evidence

Comment on "real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure".

Source reference associated with Teduglutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1016/j.clnesp.2026.105083
PubMed
42674361
Open original source
2016Insufficient evidence

Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition.

Content-verified record concerning Teduglutide: "Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition." Abstract excerpt: Glucagon-like peptide 2 (GLP-2) agonists decrease the need for parenteral nutrition (PN) in short bowel syndrome (SBS); mechanisms evaluated to date have focused on the intestinotrophic effect of GLP-2 agonists such as increased absorptive capacity of the remnant intestine and increased citrulline levels. Other mechanisms may also play a role in effects of GLP-2 agonists. To measure effects of a G

Source
peer_reviewed_research
DOI
10.1177/0148607115597644
PubMed
26223941
Open original source
2026Insufficient evidence

Association between teduglutide treatment and long-term reductions in parenteral support: An observational cohort study of adults with short bowel syndrome.

Content-verified record concerning Teduglutide: "Association between teduglutide treatment and long-term reductions in parenteral support: An observational cohort study of adults with short bowel syndrome." Abstract excerpt: Teduglutide is indicated for the treatment of patients with short bowel syndrome with intestinal failure (SBS-IF) who are dependent on parenteral support. This study aimed to evaluate the association between teduglutide treatment and changes in parenteral support requirements in adult patients with SBS-IF in a real-world setting. This study was an observational, retrospective study of adult patien

Source
peer_reviewed_research
DOI
10.1016/j.clnesp.2026.103440
PubMed
42373043
Open original source
2025Insufficient evidence

Safety of Teduglutide for Managing Patients with Short Bowel Syndrome: A Systematic Review and Meta-analysis.

Content-verified record concerning Teduglutide: "Safety of Teduglutide for Managing Patients with Short Bowel Syndrome: A Systematic Review and Meta-analysis." Abstract excerpt: Short bowel syndrome (SBS), characterized by insufficient absorptive surface after extensive intestinal resection, results in chronic intestinal failure and reliance on parenteral nutrition. This meta-analysis aimed to examine the adverse events associated with teduglutide treatment for SBS. Comprehensive search was conducted in PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTR

Source
systematic_review_or_meta_analysis
DOI
10.12669/pjms.41.9.12604
PubMed
41070320
Open original source
2025Insufficient evidence

Impact of teduglutide on pediatric short bowel syndrome: A systematic review and trial sequential meta-analysis.

Content-verified record concerning Teduglutide: "Impact of teduglutide on pediatric short bowel syndrome: A systematic review and trial sequential meta-analysis." Abstract excerpt: Pediatric short bowel syndrome (SBS) poses management challenges, and teduglutide is a potential therapy. However, comprehensive data on its pediatric safety are lacking. To evaluate the impact of teduglutide on infection and gastrointestinal adverse events in pediatric SBS patients via systematic review and meta-analysis. Following PRISMA 2009 guidelines and PROSPERO registration, we searched Pub

Source
systematic_review_or_meta_analysis
DOI
10.4240/wjgs.v17.i12.112685
PubMed
41479721
Open original source
2023Insufficient evidence

Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure.

Content-verified record concerning Teduglutide: "Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure." Abstract excerpt: This post-hoc analysis evaluated the effect of teduglutide treatment on diarrhea in patients with short bowel syndrome-associated intestinal failure (SBS-IF). Data from 2 open-label, multicenter, phase 3 pediatric SBS-IF clinical trials of teduglutide (NCT01952080 and NCT02682381) were pooled where possible. The primary objective was to evaluate the change in stool consistency, frequency, and volu

Source
peer_reviewed_research
DOI
10.1097/mpg.0000000000003922
PubMed
37889619
Open original source
2026Insufficient evidence

Optimizing teduglutide treatment regimens in children with short bowel syndrome.

Content-verified record concerning Teduglutide: "Optimizing teduglutide treatment regimens in children with short bowel syndrome." Abstract excerpt: Short bowel syndrome (SBS) is the main cause of intestinal failure (IF) in children, leading to severe malabsorption and dependence on parenteral nutrition (PN). The glucagon-like peptide-2(GLP-2) analogue teduglutide (TED) has emerged as the disease-specific treatment strategy capable of stimulating intestinal adaptation to promote PN reduction. In recent years, new randomized pediatric trials an

Source
systematic_review_or_meta_analysis
DOI
10.3389/fped.2026.1898958
PubMed
42591359
Open original source
2012Insufficient evidence

Treatment of adult short bowel syndrome patients with teduglutide.

Content-verified record concerning Teduglutide: "Treatment of adult short bowel syndrome patients with teduglutide." Abstract excerpt: Parenteral support is lifesaving in short bowel syndrome patients with intestinal failure (SBS-IF), who are unable to compensate for their malabsorption by metabolic or pharmacologic adaptation. Mutually, the symptoms of SBS-IF and the inconveniences and complications in relation to parenteral support may cause impairment of the quality of life of SBS-IF patients. Conventional treatments include d

Source
peer_reviewed_research
DOI
10.1517/14656566.2012.644787
PubMed
22224470
Open original source
2022Insufficient evidence

Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis.

Content-verified record concerning Teduglutide: "Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis." Abstract excerpt: Teduglutide has been described as an effective treatment for parenteral support (PS) reduction in patients with short bowel syndrome (SBS). However, a quantitative summary of the available evidence is still lacking. PubMed/Medline, EMBASE, Cochrane library, OVID, and CINAHL databases were systematically searched up to July 2021 for studies reporting the rate of response (defined as a ≥20% r

Source
systematic_review_or_meta_analysis
DOI
10.3390/nu14040796
PubMed
35215445
Open original source
2018Insufficient evidence

GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting.

Content-verified record concerning Teduglutide: "GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting." Abstract excerpt: To evaluate the benefits of teduglutide in a real-life setting, we analyzed the data of 14 patients with short bowel syndrome treated with teduglutide. Additionally, we studied glucagon-like peptide 2 (GLP-2) receptor expression in samples of small intestinal and colonic tissue to provide explanations for clinical observations. Stool frequency and consistency, sensation of thirst, parental calorie

Source
peer_reviewed_research
DOI
10.1177/1756284818793343
PubMed
30364471
Open original source
2019Insufficient evidence

Experience with teduglutide treatment for short bowel syndrome in clinical practice.

Content-verified record concerning Teduglutide: "Experience with teduglutide treatment for short bowel syndrome in clinical practice." Abstract excerpt: Teduglutide, a glucagon-like peptide 2 (GLP-2) analog, is an approved medication specific for short bowel syndrome patients with chronic intestinal failure (SBS-IF). Due to its intestinotrophic properties, it improves intestinal absorption of fluids and nutrients, which was shown to reduce the need for parenteral support in clinical trials. The present report aims to describe the experience of ted

Source
peer_reviewed_research
DOI
10.1016/j.clnu.2018.07.030
PubMed
30145039
Open original source
2021Insufficient evidence

Designing Novel Teduglutide Analogues with Improved Binding Affinity: An In Silico Peptide Engineering Approach.

Content-verified record concerning Teduglutide: "Designing Novel Teduglutide Analogues with Improved Binding Affinity: An In Silico Peptide Engineering Approach." Abstract excerpt: Short bowel syndrome (SBS) is a disabling condition that occurs following the loss of substantial portions of the intestine, leading to inadequate absorption of nutrients and fluids. Teduglutide is the only drug that has been FDA-approved for long-term treatment of SBS. This medicine exerts its biological effects through binding to the GLP-2 receptor. The current study aimed to use computational m

Source
peer_reviewed_research
DOI
10.2174/1573409916666200217091456
PubMed
32065094
Open original source
2020Insufficient evidence

Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data.

Content-verified record concerning Teduglutide: "Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data." Abstract excerpt: The aim of the study was to describe the experience with teduglutide of several Spanish hospitals in pediatric patients with SBS (SBS). Seventeen pediatric patients with intestinal failure associated with SBS were treated with teduglutide. Patients received 0.05 mg · kg · day of subcutaneous teduglutide. Patients' demographics and changes in parenteral

Source
peer_reviewed_research
DOI
10.1097/mpg.0000000000002899
PubMed
32804906
Open original source
2020Insufficient evidence

Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials.

Content-verified record concerning Teduglutide: "Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials." Abstract excerpt: Teduglutide response, in terms of parenteral support (PS) volume reduction, is associated with specific disease characteristics among adults with short bowel syndrome-associated intestinal failure (SBS-IF). Whether these associations apply to PS weaning with teduglutide is unknown. Adults with SBS-IF treated with teduglutide in the phase III STEPS study and open-label extensions STEPS-2 and STEPS-

Source
peer_reviewed_research
DOI
10.1002/jpen.1687
PubMed
31423614
Open original source
2013Insufficient evidence

Pharmacokinetics of teduglutide in subjects with renal impairment.

Content-verified record concerning Teduglutide: "Pharmacokinetics of teduglutide in subjects with renal impairment." Abstract excerpt: Teduglutide is a recombinant analogue of human glucagon-like peptide-2 that has recently been approved for the treatment of short bowel syndrome in adults. This study was designed to study the influence of renal function and age on teduglutide pharmacokinetics. This was an open-label study with six parallel groups (6 subjects each). Three groups with renal impairment (moderate, severe and end-stag

Source
peer_reviewed_research
DOI
10.1007/s00228-012-1455-7
PubMed
23187965
Open original source
2020Insufficient evidence

[Is there life after teduglutide?]

Content-verified record concerning Teduglutide: "[Is there life after teduglutide?]" Abstract excerpt: Intestinal failure (IF) is defined as a reduction in intestinal function below the minimum necessary for the absorption of nutrients, requiring intravenous supplementation to maintain health and/or growth. The most common cause is short bowel syndrome (SBS). Approximately 50% of patients with SBS have IF and require parenteral support. Teduglutide is a human glucagon-like peptide-2 analogue (GLP-2

Source
peer_reviewed_research
DOI
10.20960/nh.03052
PubMed
32406744
Open original source
2017Insufficient evidence

Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.

Content-verified record concerning Teduglutide: "Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome." Abstract excerpt: To determine safety and pharmacodynamics/efficacy of teduglutide in children with intestinal failure associated with short bowel syndrome (SBS-IF). This 12-week, open-label study enrolled patients aged 1-17 years with SBS-IF who required parenteral nutrition (PN) and showed minimal or no advance in enteral nutrition (EN) feeds. Patients enrolled sequentially into 3 teduglutide cohorts (0.0125 mg/k

Source
peer_reviewed_research
DOI
10.1016/j.jpeds.2016.10.027
PubMed
27855998
Open original source
2023Insufficient evidence

Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.

Content-verified record concerning Teduglutide: "Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support." Abstract excerpt: Our objective was to evaluate the short- and long-term safety and efficacy of teduglutide treatment in infants and children with short bowel syndrome with intestinal failure (SBS-IF). Two open-label phase 3 studies and 1 extension study investigated the short- and long-term safety and efficacy of teduglutide (0.05 mg/kg/day) in infants and children with SBS-IF: NCT03571516, 24-week study of infant

Source
peer_reviewed_research
DOI
10.1097/mpg.0000000000003867
PubMed
37364133
Open original source
Insufficient evidence

PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.

Source reference associated with Teduglutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1002/jpr3.70144
PubMed
42110144
Open original source
2013Insufficient evidence

Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.

Content-verified record concerning Teduglutide: "Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure." Abstract excerpt: Although home parenteral nutrition (PN) can save the lives of patients with massive bowel loss that results in short-bowel syndrome and intestinal failure, quality of life is impaired by PN and its complications. We examined the 12-month tolerability and efficacy of teduglutide to reduce PN dependency. Patients who received teduglutide (0.05 or 0.10 mg/kg/d) for 24 weeks in a randomized controlled

Source
peer_reviewed_research
DOI
10.1016/j.cgh.2012.12.029
PubMed
23333663
Open original source
2012Insufficient evidence

A Thorough QT Study of Teduglutide in Healthy Subjects.

Content-verified record concerning Teduglutide: "A Thorough QT Study of Teduglutide in Healthy Subjects." Abstract excerpt: Teduglutide, an analog of the endogenous hormone glucagon-like peptide-2, is currently being developed for the treatment of short bowel syndrome. This study investigated the potential effects of teduglutide on cardiac conduction and repolarization. Seventy-two healthy volunteers underwent 4 treatment periods in randomized order with a single subcutaneous injection of placebo, 5 and 20 mg tedugluti

Source
peer_reviewed_research
DOI
10.1177/2160763x12438745
PubMed
27121220
Open original source
Insufficient evidence

Add-on to current guidelines for monitoring of SBS patients treated with teduglutide

Source reference associated with Teduglutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1038/s44355-025-00047-7
Open original source
2021Insufficient evidence

Safety Findings in Pediatric Patients During Long-Term Treatment With Teduglutide for Short-Bowel Syndrome-Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies.

Content-verified record concerning Teduglutide: "Safety Findings in Pediatric Patients During Long-Term Treatment With Teduglutide for Short-Bowel Syndrome-Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies." Abstract excerpt: This analysis assessed combined safety data from 4 clinical studies of teduglutide in pediatric patients with short-bowel syndrome-associated intestinal failure (SBS-IF). Safety data from teduglutide-treated patients in 4 clinical trials were pooled. The completed 12-week and 24-week phase 3 core studies (NCT01952080/EudraCT 2013-004588-30 and NCT02682381/EudraCT 2015-002252-27) enrolled children

Source
peer_reviewed_research
DOI
10.1002/jpen.2061
PubMed
33305440
Open original source
2024Insufficient evidence

Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals.

Content-verified record concerning Teduglutide: "Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals." Abstract excerpt: This study aimed to gain real-world insights from healthcare professionals (HCPs) regarding the management of adult patients with short bowel syndrome and intestinal failure (SBS-IF) who received teduglutide and achieved parenteral support (PS) independence or PS volume stability for ≥12 months. This cross-sectional survey was conducted in five European countries and Canada via a self-repor

Source
peer_reviewed_research
DOI
10.3390/nu16213762
PubMed
39519595
Open original source
2023Insufficient evidence

Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome.

Content-verified record concerning Teduglutide: "Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome." Abstract excerpt: Short bowel syndrome (SBS) is the main cause of intestinal failure in children. This single-center study evaluated the safety and efficacy of teduglutide in pediatric patients with SBS-associated intestinal failure (SBS-IF). Children with SBS followed at our center with ≥2 y on parenteral nutrition (PN) and with small bowel length <80 cm who had reached a plateau were consecutively inclu

Source
peer_reviewed_research
DOI
10.1016/j.ajcnut.2023.02.019
PubMed
37270289
Open original source
Insufficient evidence

Effectiveness and Safety of Teduglutide Treatment in Adult Patients with Short Bowel Syndrome: A Case Series and Review of Current Evidence.

Source reference associated with Teduglutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.3390/jcm15052033
PubMed
41827448
Open original source
2018Insufficient evidence

Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study.

Content-verified record concerning Teduglutide: "Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study." Abstract excerpt: Patients with intestinal failure associated with short bowel syndrome (SBS-IF) require parenteral support (PS) to maintain fluid balance or nutrition. Teduglutide (TED) reduced PS requirements in patients with SBS-IF in the randomized, placebo (PBO)-controlled STEPS study (NCT00798967) and its 2-year, open-label extension, STEPS-2 (NCT00930644). STEPS-3 (NCT01560403), a 1-year, open-label extensio

Source
peer_reviewed_research
DOI
10.1002/ncp.10092
PubMed
29761915
Open original source
2013Insufficient evidence

Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome.

Content-verified record concerning Teduglutide: "Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome." Abstract excerpt: Intestinotrophic therapies, such as glucagon-like peptide-2 (GLP-2) analogs, may enhance intestinal adaptation and reduce dependence on parenteral nutrition (PN) in patients with intestinal failure associated with short bowel syndrome (SBS-IF). However, because GLP-2 enhances cellular growth, there is concern that GLP-2 analogs may also encourage growth of malignant cells. To histologically examin

Source
peer_reviewed_research
DOI
10.1097/mcg.0b013e3182828f57
PubMed
23426461
Open original source
2008Insufficient evidence

Teduglutide in intestinal adaptation and repair: light at the end of the tunnel.

Content-verified record concerning Teduglutide: "Teduglutide in intestinal adaptation and repair: light at the end of the tunnel." Abstract excerpt: Malabsorption of nutrients, fluids and electrolytes is a key finding in patients with short bowel syndrome. If not compensated for by increased intake, it leads to diminished body stores and subclinical, and eventually clinical, deficiencies. Until recently, management options were limited to interventions aimed at provision of adequate macro- and micronutrients and fluids to prevent malnutrition,

Source
peer_reviewed_research
DOI
10.1517/13543784.17.6.945
PubMed
18491995
Open original source
2026Insufficient evidence

Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide.

Content-verified record concerning Teduglutide: "Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide." Abstract excerpt: The complex care needs of pediatric patients with short bowel syndrome-associated intestinal failure (SBS-IF) can negatively impact the health-related quality of life (HRQoL) of patients and their caregivers. We assessed the impact of teduglutide on HRQoL of pediatric patients with SBS-IF. Two long-term extension (LTE) studies (NCT02949362, NCT02954458) assessed HRQoL over 96 weeks using the Pedia

Source
peer_reviewed_research
DOI
10.1002/jpn3.70358
PubMed
41858082
Open original source
2023Insufficient evidence

Teduglutide for the treatment of short bowel syndrome: a double-edged sword?

Content-verified record concerning Teduglutide: "Teduglutide for the treatment of short bowel syndrome: a double-edged sword?" (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1016/j.ajcnut.2023.04.009
PubMed
37270286
Open original source
2016Insufficient evidence

Teduglutide and Intestinal Permeability in Short Bowel Syndrome.

Content-verified record concerning Teduglutide: "Teduglutide and Intestinal Permeability in Short Bowel Syndrome." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1177/0148607116637847
PubMed
27875268
Open original source
2013Insufficient evidence

Teduglutide injection (Gattex) for short bowel syndrome.

Content-verified record concerning Teduglutide: "Teduglutide injection (Gattex) for short bowel syndrome." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
PubMed
23588102
Open original source
2012Insufficient evidence

Teduglutide and short bowel syndrome: every night without parenteral fluids is a good night.

Content-verified record concerning Teduglutide: "Teduglutide and short bowel syndrome: every night without parenteral fluids is a good night." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1053/j.gastro.2012.10.022
PubMed
23089542
Open original source
2024Insufficient evidence

Use of teduglutide in adults with short bowel syndrome-associated intestinal failure.

Content-verified record concerning Teduglutide: "Use of teduglutide in adults with short bowel syndrome-associated intestinal failure." Abstract excerpt: Short bowel syndrome (SBS) is a rare gastrointestinal disorder associated with intestinal failure (SBS-IF) and poor health-related outcomes. Patients with SBS-IF are unable to absorb sufficient nutrients or fluids to maintain significantly metabolic homeostasis via oral or enteral intake alone and require long-term intravenous supplementation (IVS), consisting of partial or total parenteral nutrit

Source
peer_reviewed_research
DOI
10.1002/ncp.11015
PubMed
37294295
Open original source
2014Insufficient evidence

Utility of a population pharmacokinetic meta analysis during the approval process of teduglutide for the treatment of short bowel syndrome.

Content-verified record concerning Teduglutide: "Utility of a population pharmacokinetic meta analysis during the approval process of teduglutide for the treatment of short bowel syndrome." Abstract excerpt: Teduglutide is a recombinant analogue of human glucagonlike peptide-2 (GLP-2) that was recently approved by the US and European regulatory agencies FDA and EMA for the treatment of short bowel syndrome (SBS). The objectives of this work were, firstly, to develop a population pharmacokinetic (popPK) model based on the available PK data of the entire clinical development program and, secondly, to ut

Source
systematic_review_or_meta_analysis
DOI
10.5414/cp201942
PubMed
25066226
Open original source
2026Insufficient evidence

[Use of teduglutide in short bowel syndrome in infants, children and adolescents: Position paper of the working group "Chronic intestinal failure" of the Society for Paediatric Gastroenterology and Nutrition (GPGE)].

Content-verified record concerning Teduglutide: "[Use of teduglutide in short bowel syndrome in infants, children and adolescents: Position paper of the working group "Chronic intestinal failure" of the Society for Paediatric Gastroenterology and Nutrition (GPGE)]." Abstract excerpt: Paediatric short bowel syndrome (SBS) with chronic intestinal failure (IF) is a rare, complex and potentially life-threatening condition. The main causes in children are necrotizing enterocolitis, volvulus, congenital malformations, and other enteropathies. The resulting reduced intestinal absorption capacity often requires parenteral nutrition (PN), which is associated with complications such as

Source
systematic_review_or_meta_analysis
DOI
10.1055/a-2757-3525
PubMed
41672430
Open original source
2013Insufficient evidence

Study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel syndrome subjects.

Content-verified record concerning Teduglutide: "Study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel syndrome subjects." Abstract excerpt: Loss of intestinal absorptive capacity from congenital defect, surgical resection or mucosal disease results in short bowel syndrome (SBS)-associated intestinal failure. In the past, few medical management options were available besides dietary modification, controlling diarrhea or high stomal output, and providing parenteral fluid, electrolyte and nutrient support (parenteral support). Recent res

Source
peer_reviewed_research
DOI
10.1586/17474124.2013.842894
PubMed
24134154
Open original source
Insufficient evidence

Safety and long-term effectiveness of teduglutide in children with intestinal failure due to short bowel syndrome: a multicenter, post-marketing cohort study.

Source reference associated with Teduglutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1038/s41390-026-05489-0
PubMed
42754721
Open original source
2011Insufficient evidence

Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome.

Content-verified record concerning Teduglutide: "Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome." Abstract excerpt: Teduglutide was discontinued after being tested for ≥ 24 weeks in patients with parenteral nutrition (PN) -dependent short bowel syndrome in a clinical trial for efficacy to reduce PN volume. This study was describes change in body mass index (BMI) and PN volume over 12 months in patients who stopped drug after the clinical trial. Prescribed PN volume, weight, and complications were reporte

Source
peer_reviewed_research
DOI
10.1177/0148607111414431
PubMed
21825090
Open original source
2017Insufficient evidence

Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.

Content-verified record concerning Teduglutide: "Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome." Abstract excerpt: In phase III clinical studies, treatment with teduglutide was associated with clinically meaningful reductions (≥20% from baseline) in parenteral support (PS; parenteral nutrition and/or intravenous fluids) requirements in adult patients with intestinal failure associated with short bowel syndrome (SBS-IF). This analysis reports clinical characteristics of patients who achieved complete ind

Source
peer_reviewed_research
DOI
10.1177/0148607116680791
PubMed
27875291
Open original source
2026Insufficient evidence

Assessing the health-related quality of life and clinical effect in children with short bowel syndrome receiving teduglutide treatment.

Content-verified record concerning Teduglutide: "Assessing the health-related quality of life and clinical effect in children with short bowel syndrome receiving teduglutide treatment." Abstract excerpt: Short bowel syndrome (SBS) imposes a substantial burden on pediatric patients and their caregivers. Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, promotes intestinal adaptation by enhancing villus hyperplasia and crypt deepening. This study aimed to evaluate its impact on the health-related quality of life (HRQoL) of children with SBS and their caregivers. In this matched case-control stu

Source
peer_reviewed_research
DOI
10.1186/s12887-026-07283-7
PubMed
42410547
Open original source
2018Insufficient evidence

Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.

Content-verified record concerning Teduglutide: "Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure." Abstract excerpt: Clinical studies showed teduglutide to increase urine production and reduce need for parenteral support volume in patients with short bowel syndrome (SBS) with intestinal failure, increasing intestinal wet weight absorption and reducing diarrhea. However, the effects of teduglutide on parenteral support vary among patients. We performed a post hoc analysis of a phase III placebo-controlled study t

Source
peer_reviewed_research
DOI
10.1053/j.gastro.2017.11.023
PubMed
29174926
Open original source
2009Insufficient evidence

Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome.

Content-verified record concerning Teduglutide: "Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome." Abstract excerpt: Teduglutide, a synthetic glucagon-like peptide-2 (GLP-2) analog with activity relating to the regeneration, maintenance, and repair of the intestinal epithelium, is currently being evaluated for the treatment of short-bowel syndrome (SBS), Crohn's disease, and other gastrointestinal disorders. On the basis of promising results from teduglutide studies in adults with SBS and from studies in neonata

Source
peer_reviewed_research
DOI
10.1038/clpt.2009.199
PubMed
19847163
Open original source
2013Insufficient evidence

[Short bowel syndrome. GLP-2 analog teduglutide].

Content-verified record concerning Teduglutide: "[Short bowel syndrome. GLP-2 analog teduglutide]." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
PubMed
24069647
Open original source
2021Insufficient evidence

Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support.

Content-verified record concerning Teduglutide: "Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support." Abstract excerpt: This study aimed to identify predictors and estimate time to teduglutide response among adult patients with short bowel syndrome with intestinal failure (SBS-IF) dependent on parenteral support (PS). Post-hoc analysis was performed on individual patient data from teduglutide-treated patients in the phase III teduglutide trial STEPS and the STEPS-2 extension. Response was defined as ≥20% PS

Source
peer_reviewed_research
DOI
10.1016/j.clnesp.2021.03.011
PubMed
34024550
Open original source
2026Insufficient evidence

A case report on the long-term use of teduglutide in a pediatric patient with short bowel syndrome.

Content-verified record concerning Teduglutide: "A case report on the long-term use of teduglutide in a pediatric patient with short bowel syndrome." Abstract excerpt: Short bowel syndrome (SBS) is the leading cause of intestinal failure, frequently necessitating long-term parenteral nutrition (PN). Teduglutide (TED), a glucagon-like peptide-2 analog, has demonstrated efficacy in reducing PN dependence in both adults and children. However, long-term data in pediatric populations remain limited. We present a case of a male child with SBS who underwent extensive s

Source
peer_reviewed_research
DOI
10.1002/ncp.70023
PubMed
40886056
Open original source
2026Insufficient evidence

Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance.

Content-verified record concerning Teduglutide: "Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance." Abstract excerpt: Patients with intestinal failure caused by short bowel syndrome (SBS) are dependent on parenteral support (PS) for nutrition. Teduglutide, an analogue of glucagon-like peptide 2, has been shown to decrease reliance on PS with an acceptable safety profile in multiregional phase 3 clinical trials, but currently there are no reports examining treatment outcomes with teduglutide in the real-

Source
peer_reviewed_research
DOI
10.1007/s12325-025-03398-y
PubMed
41324792
Open original source
2018Insufficient evidence

Single-Center Experience with the Use of Teduglutide in Adult Patients with Short Bowel Syndrome.

Content-verified record concerning Teduglutide: "Single-Center Experience with the Use of Teduglutide in Adult Patients with Short Bowel Syndrome." Abstract excerpt: Teduglutide is a glucagon-like peptide 2 (GLP-2) analog that has been approved for the treatment of adult short bowel syndrome (SBS)-associated intestinal failure (IF; SBS-IF). Teduglutide increases villus height and crypt depth in the small bowel mucosa, promoting nutrition absorption and enteral independence from parenteral nutrition (PN). We aim to report our single-center experience with tedug

Source
peer_reviewed_research
DOI
10.1002/jpen.1011
PubMed
29505151
Open original source
Insufficient evidence

Teduglutide in Enterocolitis Secondary to Graft-Versus-Host Disease Post-Bone Transplant: Case Report

Source reference associated with Teduglutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.20944/preprints202602.1566.v1
Open original source
Insufficient evidence

Real-world effectiveness and safety of teduglutide in patients with short bowel syndrome.

Source reference associated with Teduglutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.4292/wjgpt.v17.i1.117071
PubMed
41809219
Open original source
2023Insufficient evidence

Adult patients with short bowel syndrome treated with teduglutide: A descriptive cohort study.

Content-verified record concerning Teduglutide: "Adult patients with short bowel syndrome treated with teduglutide: A descriptive cohort study." Abstract excerpt: Teduglutide is a synthetic glucagon-like peptide-2 analogue approved for the treatment of short bowel syndrome associated with chronic intestinal failure (SBS-IF) in adult patients. Clinical trials have demonstrated its ability to reduce parenteral support (PS) requirement. This study aimed to describe the effect of 18-month treatment with teduglutide, evaluating PS and factors associated with PS

Source
peer_reviewed_research
DOI
10.1002/jpen.2549
PubMed
37416984
Open original source
2024Insufficient evidence

Long-term outcomes and adverse effects of teduglutide in patients with short bowel syndrome: Highlighting hyperamylasemia and hyperlipasemia.

Content-verified record concerning Teduglutide: "Long-term outcomes and adverse effects of teduglutide in patients with short bowel syndrome: Highlighting hyperamylasemia and hyperlipasemia." Abstract excerpt: Short bowel syndrome is a malabsorptive condition that occurs due to surgical removal or a congenital absence of a significant portion of the small intestine. Patients with short bowel syndrome often rely on parenteral support for extended periods or even their entire lives. Teduglutide, a glucagon-like peptide-2 analog, has shown promising results in reducing dependency on parenteral support in t

Source
systematic_review_or_meta_analysis
DOI
10.1093/ajhp/zxad274
PubMed
37941451
Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓
Chemical identity

Molecular and structural record

Structured record
Molecular formula
C164H252N44O55S
Molecular weight (Da)
3752.1
SMILES
CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)O)NC(=O)C(CCCCN)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC(=O)N)NC(=O)C(C(C)CC)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CC(=O)N)NC(=O)C(CCSC)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CO)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC5=CN=CN5)N
InChI
InChI=1S/C164H252N44O55S/c1-21-77(11)126(156(255)187-95(44-46-114(167)214)141(240)206-130(83(17)211)160(259)186-93(42-33-34-49-165)140(239)202-129(80(14)24-4)159(258)208-131(84(18)212)161(260)200-111(163(262)263)66-125(230)231)203-151(250)100(54-76(9)10)189-145(244)103(57-88-67-175-92-41-32-31-40-90(88)92)192-147(246)105(60-116(169)216)199-157(256)127(78(12)22-2)204-152(251)102(56-87-38-29-26-30-39-87)190-149(248)109(64-123(226)227)195-137(236)94(43-35-50-174-164(171)172)183-134(233)82(16)179-133(232)81(15)180-142(241)98(52-74(5)6)188-146(245)104(59-115(168)215)194-150(249)110(65-124(228)229)196-143(242)99(53-75(7)8)198-158(257)128(79(13)23-3)205-162(261)132(85(19)213)207-153(252)106(61-117(170)217)193-139(238)97(48-51-264-20)185-138(237)96(45-47-120(220)221)184-148(247)108(63-122(224)225)197-155(254)113(72-210)201-144(243)101(55-86-36-27-25-28-37-86)191-154(253)112(71-209)182-119(219)70-177-136(235)107(62-121(222)223)181-118(218)69-176-135(234)91(166)58-89-68-173-73-178-89/h25-32,36-41,67-68,73-85,91,93-113,126-132,175,209-213H,21-24,33-35,42-66,69-72,165-166H2,1-20H3,(H2,167,214)(H2,168,215)(H2,169,216)(H2,170,217)(H,173,178)(H,176,234)(H,177,235)(H,179,232)(H,180,241)(H,181,218)(H,182,219)(H,183,233)(H,184,247)(H,185,237)(H,186,259)(H,187,255)(H,188,245)(H,189,244)(H,190,248)(H,191,253)(H,192,246)(H,193,238)(H,194,249)(H,195,236)(H,196,242)(H,197,254)(H,198,257)(H,199,256)(H,200,260)(H,201,243)(H,202,239)(H,203,250)(H,204,251)(H,205,261)(H,206,240)(H,207,252)(H,208,258)(H,220,221)(H,222,223)(H,224,225)(H,226,227)(H,228,229)(H,230,231)(H,262,263)(H4,171,172,174)/t77-,78-,79-,80-,81-,82-,83+,84+,85+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,126-,127-,128-,129-,130-,131-,132-/m0/s1
InChIKey
CILIXQOJUNDIDU-ASQIGDHWSA-N

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Research discovery

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

  1. 2004 · study · Temporal status not established

    Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage.

    peer_reviewed_research

  2. 2005 · study · Temporal status not established

    Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.

    peer_reviewed_research

  3. 2006 · study · Temporal status not established

    Teduglutide for the treatment of short bowel syndrome.

    peer_reviewed_research

  4. 2006 · study · Temporal status not established

    Teduglutide

    other

  5. 2008 · study · Temporal status not established

    Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects.

    peer_reviewed_research

  6. 2008 · study · Temporal status not established

    Teduglutide in intestinal adaptation and repair: light at the end of the tunnel.

    peer_reviewed_research

  7. 2009 · study · Temporal status not established

    Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome.

    peer_reviewed_research

  8. 2010 · study · Temporal status not established

    Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease.

    peer_reviewed_research

  9. 2010 · study · Temporal status not established

    Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.

    peer_reviewed_research

  10. 2010 · study · Temporal status not established

    Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

    peer_reviewed_research

  11. 2011 · study · Temporal status not established

    Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.

    peer_reviewed_research

  12. 2011 · study · Temporal status not established

    Effect of different doses of GLP-2 (Teduglutide) on acute esophageal lesion due to acid-pepsin perfusion in male rats.

    peer_reviewed_research

  13. 2011 · study · Temporal status not established

    Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome.

    peer_reviewed_research

  14. 2012 · study · Temporal status not established

    Teduglutide, a glucagon-like peptide 2 analogue: a novel protective agent with anti-apoptotic and anti-oxidant properties in mice with lung injury.

    peer_reviewed_research

  15. 2012 · study · Temporal status not established

    Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.

    peer_reviewed_research

  16. 2012 · study · Temporal status not established

    Treatment of adult short bowel syndrome patients with teduglutide.

    peer_reviewed_research

  17. 2012 · study · Temporal status not established

    A Thorough QT Study of Teduglutide in Healthy Subjects.

    peer_reviewed_research

  18. 2012 · study · Temporal status not established

    Teduglutide and short bowel syndrome: every night without parenteral fluids is a good night.

    peer_reviewed_research

  19. 2013 · study · Temporal status not established

    Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.

    peer_reviewed_research

  20. 2013 · study · Temporal status not established

    Teduglutide for the treatment of short bowel syndrome.

    peer_reviewed_research

  21. 2013 · study · Temporal status not established

    Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells.

    peer_reviewed_research

  22. 2013 · study · Temporal status not established

    The long road to a new short-bowel therapy: teduglutide for clinical use.

    peer_reviewed_research

  23. 2013 · study · Temporal status not established

    Teduglutide: a review of its use in the treatment of patients with short bowel syndrome.

    peer_reviewed_research

  24. 2013 · study · Temporal status not established

    Increased intestinal absorption in the era of teduglutide and its impact on management strategies in patients with short bowel syndrome-associated intestinal failure.

    peer_reviewed_research

  25. 2013 · study · Temporal status not established

    Pharmacokinetics of teduglutide in subjects with renal impairment.

    peer_reviewed_research

  26. 2013 · study · Temporal status not established

    Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure.

    peer_reviewed_research

  27. 2013 · study · Temporal status not established

    Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome.

    peer_reviewed_research

  28. 2013 · study · Temporal status not established

    Teduglutide injection (Gattex) for short bowel syndrome.

    peer_reviewed_research

  29. 2013 · study · Temporal status not established

    Study of teduglutide effectiveness in parenteral nutrition-dependent short-bowel syndrome subjects.

    peer_reviewed_research

  30. 2013 · study · Temporal status not established

    [Short bowel syndrome. GLP-2 analog teduglutide].

    peer_reviewed_research

  31. 2014 · study · Temporal status not established

    A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.

    peer_reviewed_research

  32. 2014 · study · Temporal status not established

    Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.

    peer_reviewed_research

  33. 2014 · study · Temporal status not established

    Vortioxetine hydrobromide, crofelemer, and teduglutide.

    peer_reviewed_research

  34. 2014 · study · Temporal status not established

    Teduglutide for the Treatment of Short Bowel Syndrome.

    peer_reviewed_research

  35. 2014 · study · Temporal status not established

    Utility of a population pharmacokinetic meta analysis during the approval process of teduglutide for the treatment of short bowel syndrome.

    systematic_review_or_meta_analysis

  36. 2015 · study · Temporal status not established

    Effect of Teduglutide, a Glucagon-like Peptide 2 Analog, on Citrulline Levels in Patients With Short Bowel Syndrome in Two Phase III Randomized Trials.

    peer_reviewed_research

  37. 2015 · study · Temporal status not established

    [Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) for teduglutide-benefit assessment according to § 35a SGB V the G-BA].

    peer_reviewed_research

  38. 2015 · study · Temporal status not established

    Teduglutide: a guide to its use in short bowel syndrome.

    peer_reviewed_research

  39. 2016 · study · Temporal status not established

    Response to "Teduglutide and Intestinal Permeability in Short Bowel Syndrome".

    peer_reviewed_research

  40. 2016 · study · Temporal status not established

    A Patient With Parenteral Nutrition-Dependent Short Bowel Syndrome and Cardiovascular Disease With 4-Year Exposure to Teduglutide.

    peer_reviewed_research

  41. 2016 · study · Temporal status not established

    Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review.

    systematic_review_or_meta_analysis

  42. 2016 · study · Temporal status not established

    Clinical Management of Patients With Parenteral Nutrition-Dependent Short Bowel Syndrome During Teduglutide Therapy.

    peer_reviewed_research

  43. 2016 · study · Temporal status not established

    Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome.

    peer_reviewed_research

  44. 2016 · study · Temporal status not established

    Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition.

    peer_reviewed_research

  45. 2016 · study · Temporal status not established

    Teduglutide and Intestinal Permeability in Short Bowel Syndrome.

    peer_reviewed_research

  46. 2017 · study · Temporal status not established

    Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide.

    peer_reviewed_research

  47. 2017 · study · Temporal status not established

    Enteral Autonomy with Teduglutide Treatment of Intestinal Failure/Short Bowel Syndrome with Depleted Central Venous Access.

    peer_reviewed_research

  48. 2017 · study · Temporal status not established

    Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.

    peer_reviewed_research

  49. 2017 · study · Temporal status not established

    Results of 12-month rescue treatment with Teduglutide in severely active and parenteral nutrition-dependent Crohn's disease.

    peer_reviewed_research

  50. 2017 · study · Temporal status not established

    Intestinal inflammatory and redox responses to the perioperative administration of teduglutide in rats.

    peer_reviewed_research

  51. 2017 · study · Temporal status not established

    Teduglutide effects on gene regulation of fibrogenesis on an animal model of intestinal anastomosis.

    peer_reviewed_research

  52. 2017 · study · Temporal status not established

    Teduglutide for treatment of adult patients with short bowel syndrome.

    peer_reviewed_research

  53. 2017 · study · Temporal status not established

    The Polish Intestinal Failure Centres' consensus on the use of teduglutide for the treatment of short bowel syndrome.

    peer_reviewed_research

  54. 2017 · study · Temporal status not established

    Teduglutide: A Review in Short Bowel Syndrome.

    peer_reviewed_research

  55. 2017 · study · Temporal status not established

    Teduglutide-Stimulated Intestinal Adaptation Is Complemented and Synergistically Enhanced by Partial Enteral Nutrition in a Neonatal Piglet Model of Short Bowel Syndrome.

    peer_reviewed_research

  56. 2017 · study · Temporal status not established

    Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.

    peer_reviewed_research

  57. 2017 · study · Temporal status not established

    Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.

    peer_reviewed_research

  58. 2018 · study · Temporal status not established

    Further improvement after 24-month treatment with teduglutide in a patient with active Crohn's disease and short bowel syndrome.

    peer_reviewed_research

  59. 2018 · study · Temporal status not established

    Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series.

    peer_reviewed_research

  60. 2018 · study · Temporal status not established

    De Novo Development of Hamartomatous Duodenal Polyps in a Patient With Short Bowel Syndrome During Teduglutide Therapy: A Case Report.

    peer_reviewed_research

  61. 2018 · study · Temporal status not established

    Tissular growth factors profile after teduglutide administration on an animal model of intestinal anastomosis.

    peer_reviewed_research

  62. 2018 · study · Temporal status not established

    Teduglutide-induced stem cell function in intestinal repair.

    peer_reviewed_research

  63. 2018 · study · Temporal status not established

    Intestinal Epithelial Stem Cells: Distinct Behavior After Surgical Injury and Teduglutide Administration.

    peer_reviewed_research

  64. 2018 · study · Temporal status not established

    Teduglutide for the treatment of short bowel syndrome - a safety evaluation.

    peer_reviewed_research

  65. 2018 · study · Temporal status not established

    GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting.

    peer_reviewed_research

  66. 2018 · study · Temporal status not established

    Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study.

    peer_reviewed_research

  67. 2018 · study · Temporal status not established

    Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.

    peer_reviewed_research

  68. 2018 · study · Temporal status not established

    Single-Center Experience with the Use of Teduglutide in Adult Patients with Short Bowel Syndrome.

    peer_reviewed_research

  69. 2019 · study · Temporal status not established

    Off-Label Teduglutide Therapy in Non-intestinal Failure Patients with Chronic Malabsorption.

    peer_reviewed_research

  70. 2019 · study · Temporal status not established

    Teduglutide in Patients With Active Crohn's Disease and Short Bowel Syndrome.

    peer_reviewed_research

  71. 2019 · study · Temporal status not established

    Effect of teduglutide on restoring oral autonomy for magnesium in two patients with short bowel.

    peer_reviewed_research

  72. 2019 · study · Temporal status not established

    Accelerated Colorectal Polyposis in an Immunosuppressed Patient With a Small Bowel Transplant Treated With Teduglutide: Case Report and Review of Literature.

    peer_reviewed_research

  73. 2019 · study · Temporal status not established

    Experience with teduglutide treatment for short bowel syndrome in clinical practice.

    peer_reviewed_research

  74. 2020 · study · Temporal status not established

    Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.

    peer_reviewed_research

  75. 2020 · study · Temporal status not established

    Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study.

    peer_reviewed_research

  76. 2020 · study · Temporal status not established

    GLP-2 analog Teduglutide in active Crohn's disease and short bowel syndrome: Confirmation of anti-inflammatory role and future perspectives.

    peer_reviewed_research

  77. 2020 · study · Temporal status not established

    Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study.

    peer_reviewed_research

  78. 2020 · study · Temporal status not established

    Small-Bowel Adaptation: A Case of Morphological Changes Induced by Teduglutide in Short-Bowel Syndrome With Intestinal Failure.

    peer_reviewed_research

  79. 2020 · study · Temporal status not established

    Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series.

    peer_reviewed_research

  80. 2020 · study · Temporal status not established

    Comprehensive nutritional assessment in short bowel syndrome with chronic renal failure on teduglutide therapy: A case report.

    peer_reviewed_research

  81. 2020 · study · Temporal status not established

    Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency.

    peer_reviewed_research

  82. 2020 · study · Temporal status not established

    Translation of Evidence Into Practice With Teduglutide in the Management of Adults With Intestinal Failure due to Short-Bowel Syndrome: A Review of Recent Literature.

    peer_reviewed_research

  83. 2020 · study · Temporal status not established

    Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.

    peer_reviewed_research

  84. 2020 · study · Temporal status not established

    The Glucagon-Like Peptide 2 Analog Teduglutide Reversibly Associates to Form Pentamers.

    peer_reviewed_research

  85. 2020 · study · Temporal status not established

    Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials.

    peer_reviewed_research

  86. 2020 · study · Temporal status not established

    Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure.

    peer_reviewed_research

  87. 2020 · study · Temporal status not established

    Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data.

    peer_reviewed_research

  88. 2020 · study · Temporal status not established

    Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials.

    peer_reviewed_research

  89. 2020 · study · Temporal status not established

    [Is there life after teduglutide?]

    peer_reviewed_research

  90. 2021 · study · Temporal status not established

    Long-Term Outcomes With Teduglutide From a Single Center.

    peer_reviewed_research

  91. 2021 · study · Temporal status not established

    Teduglutide Therapy in 2 Patients With Short-Bowel Syndrome and Familial Adenomatous Polyposis.

    peer_reviewed_research

  92. 2021 · study · Temporal status not established

    Imaging as predictor of clinical response to teduglutide in adult patients with short bowel syndrome with chronic intestinal failure.

    peer_reviewed_research

  93. 2021 · study · Temporal status not established

    Long-term Effects of Teduglutide on Intestinal Mucosa in a Patient With Crohn's Disease and Short Bowel Syndrome: Clinical, Endoscopic and Histological Data Compared.

    peer_reviewed_research

  94. 2021 · study · Temporal status not established

    De Novo Development of Distal Jejunal and Duodenal Adenomas After 41 Months of Teduglutide Treatment in a Patient With Short-Bowel Syndrome: A Case Report.

    peer_reviewed_research

  95. 2021 · study · Temporal status not established

    Intestinal iatrogenic hyperadaptation in patients with short bowel syndrome and Crohn's disease: Is this an indication for mandatory lifelong injections of teduglutide?

    peer_reviewed_research

  96. 2021 · study · Temporal status not established

    Expression, purification and molecular dynamics simulation of extracellular domain of glucagon-like peptide-2 receptor linked to teduglutide.

    peer_reviewed_research

  97. 2021 · study · Temporal status not established

    Cost-effectiveness of teduglutide in pediatric patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.

    peer_reviewed_research

  98. 2021 · study · Temporal status not established

    Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome.

    peer_reviewed_research

  99. 2021 · study · Temporal status not established

    Teduglutide for pediatric short bowel syndrome patients.

    systematic_review_or_meta_analysis

  100. 2021 · study · Temporal status not established

    Designing Novel Teduglutide Analogues with Improved Binding Affinity: An In Silico Peptide Engineering Approach.

    peer_reviewed_research

  101. 2021 · study · Temporal status not established

    Safety Findings in Pediatric Patients During Long-Term Treatment With Teduglutide for Short-Bowel Syndrome-Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies.

    peer_reviewed_research

  102. 2021 · study · Temporal status not established

    Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support.

    peer_reviewed_research

  103. 2022 · study · Temporal status not established

    Teduglutide for the treatment of low-output enterocutaneous fistula - A pilot randomized controlled study.

    peer_reviewed_research

  104. 2022 · study · Temporal status not established

    Long-term results of teduglutide treatment for chronic intestinal failure - Insights from a national, multi-centric patient home-care service program.

    peer_reviewed_research

  105. 2022 · study · Temporal status not established

    Characterization of American teduglutide consumers from 2015 to 2020: A large database study.

    peer_reviewed_research

  106. 2022 · study · Temporal status not established

    Hernia enlargement and pancreatitis in a patient with short bowel syndrome treated with teduglutide.

    peer_reviewed_research

  107. 2022 · study · Temporal status not established

    Changes in Parenteral Nutrition Requirements and BMI in Patients with Parenteral Nutrition-Dependent Short Bowel Syndrome after Stopping Teduglutide-9 Years of Follow-Up.

    peer_reviewed_research

  108. 2022 · study · Temporal status not established

    Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP).

    peer_reviewed_research

  109. 2022 · study · Temporal status not established

    Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers.

    peer_reviewed_research

  110. 2022 · study · Temporal status not established

    The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience.

    peer_reviewed_research

  111. 2022 · study · Temporal status not established

    Method for identification and quantification of intact teduglutide peptide using (RP)UHPLC-UV-(HESI/ORBITRAP)MS.

    peer_reviewed_research

  112. 2022 · study · Temporal status not established

    Teduglutide in short bowel syndrome patients: A way back to normal life?

    peer_reviewed_research

  113. 2022 · study · Temporal status not established

    Use of Teduglutide in Children With Intestinal Failure: A Systematic Review.

    systematic_review_or_meta_analysis

  114. 2022 · study · Temporal status not established

    Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis.

    systematic_review_or_meta_analysis

  115. 2023 · study · Temporal status not established

    Efficacy, safety, and pharmacokinetics of teduglutide in adult Japanese patients with short bowel syndrome and intestinal failure: two phase III studies with an extension.

    peer_reviewed_research

  116. 2023 · study · Temporal status not established

    Post-Marketing Use of Teduglutide in a Large Cohort of Adults with Short Bowel Syndrome-Associated Chronic Intestinal Failure: Evolution and Outcomes.

    peer_reviewed_research

  117. 2023 · study · Temporal status not established

    Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications.

    peer_reviewed_research

  118. 2023 · study · Temporal status not established

    Use of teduglutide for short bowel syndrome and Crohn's disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy.

    peer_reviewed_research

  119. 2023 · study · Temporal status not established

    Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure.

    peer_reviewed_research

  120. 2023 · study · Temporal status not established

    Unexpected upper gastrointestinal polyps in patients with short bowel syndrome treated with teduglutide: need for close monitoring.

    peer_reviewed_research

  121. 2023 · study · Temporal status not established

    Nutritional management of a patient with chronic intestinal failure and hemodialysis receiving teduglutide: A case report.

    peer_reviewed_research

  122. 2023 · study · Temporal status not established

    Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure-A Nested Matched Pair Real-World Study.

    peer_reviewed_research

  123. 2023 · study · Temporal status not established

    Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome.

    peer_reviewed_research

  124. 2023 · study · Temporal status not established

    [Expert recommendations on the use of teduglutide in pediatric patients with short bowel syndrome].

    peer_reviewed_research

  125. 2023 · study · Temporal status not established

    Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive®) structural description and stress testing.

    peer_reviewed_research

  126. 2023 · study · Temporal status not established

    Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome.

    peer_reviewed_research

  127. 2023 · study · Temporal status not established

    [Review of real-life teduglutide experience].

    peer_reviewed_research

  128. 2023 · study · Temporal status not established

    The indications and results of the use of teduglutide in patients with short bowel.

    peer_reviewed_research

  129. 2023 · study · Temporal status not established

    Effects of Teduglutide on Diarrhea in Pediatric Patients with Short Bowel Syndrome-Associated Intestinal Failure.

    peer_reviewed_research

  130. 2023 · study · Temporal status not established

    Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.

    peer_reviewed_research

  131. 2023 · study · Temporal status not established

    Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome.

    peer_reviewed_research

  132. 2023 · study · Temporal status not established

    Teduglutide for the treatment of short bowel syndrome: a double-edged sword?

    peer_reviewed_research

  133. 2023 · study · Temporal status not established

    Adult patients with short bowel syndrome treated with teduglutide: A descriptive cohort study.

    peer_reviewed_research

  134. 2024 · study · Temporal status not established

    Use of Teduglutide in the Management of Gastrointestinal Graft-versus-Host Disease in Children and Young Adults.

    peer_reviewed_research

  135. 2024 · study · Temporal status not established

    Effect of teduglutide, a glucagon-like peptide-2 analog, in eosinophilic enterocolitis: a case report.

    peer_reviewed_research

  136. 2024 · study · Temporal status not established

    Early use of teduglutide in paediatric patients with intestinal failure is associated with a greater response rate: a multicenter study.

    peer_reviewed_research

  137. 2024 · study · Temporal status not established

    The Impact of Teduglutide on Real-Life Health Care Costs in Children with Short Bowel Syndrome.

    peer_reviewed_research

  138. 2024 · study · Temporal status not established

    Cost-effectiveness of teduglutide in adult patients with short bowel syndrome - a European socioeconomic perspective.

    peer_reviewed_research

  139. 2024 · study · Temporal status not established

    Reversal of Intestinal Failure With Teduglutide in <i>PERCC1</i>-Associated Enteropathy: A Case Report.

    peer_reviewed_research

  140. 2024 · study · Temporal status not established

    Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry.

    peer_reviewed_research

  141. 2024 · study · Temporal status not established

    Orally Delivered Stimulus-Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease.

    peer_reviewed_research

  142. 2024 · study · Temporal status not established

    Cost-Effectiveness of Teduglutide for Pediatric Patients with Short Bowel Syndrome in Japan, Including Caregiver Burden.

    peer_reviewed_research

  143. 2024 · study · Temporal status not established

    Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure.

    peer_reviewed_research

  144. 2024 · study · Temporal status not established

    Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis.

    peer_reviewed_research

  145. 2024 · study · Temporal status not established

    Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals.

    peer_reviewed_research

  146. 2024 · study · Temporal status not established

    Use of teduglutide in adults with short bowel syndrome-associated intestinal failure.

    peer_reviewed_research

  147. 2024 · study · Temporal status not established

    Long-term outcomes and adverse effects of teduglutide in patients with short bowel syndrome: Highlighting hyperamylasemia and hyperlipasemia.

    systematic_review_or_meta_analysis

  148. 2025 · study · Temporal status not established

    Teduglutide in adults with short bowel syndrome and intestinal failure: A descriptive cohort study.

    peer_reviewed_research

  149. 2025 · study · Temporal status not established

    Efficacy of Teduglutide in Pediatric Short Bowel Syndrome: Association with Citrulline Levels and Anatomical Location of Remnant Small Intestine.

    peer_reviewed_research

  150. 2025 · study · Temporal status not established

    Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey.

    peer_reviewed_research

  151. 2025 · study · Temporal status not established

    Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey.

    peer_reviewed_research

  152. 2025 · study · Temporal status not established

    Forty-eight months outcomes of teduglutide treatment in adult stable patients with short bowel syndrome and home parenteral nutrition dependence: A real-world Italian single-center observational cohort study.

    peer_reviewed_research

  153. 2025 · study · Temporal status not established

    Reduction of Parenteral Nutrition in Children with Short Bowel Syndrome Treated with Teduglutide: Experience from the Czech Republic.

    peer_reviewed_research

  154. 2025 · study · Temporal status not established

    Short bowel syndrome and d-lactic acidosis: A case report with supplemental home parenteral nutrition and teduglutide.

    peer_reviewed_research

  155. 2025 · study · Temporal status not established

    Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome.

    peer_reviewed_research

  156. 2025 · study · Temporal status not established

    Encapsulation of hydrophobically ion-paired teduglutide in nanoemulsions: Effect of anionic counterions.

    peer_reviewed_research

  157. 2025 · study · Temporal status not established

    Quality of life and lived experience of patients with short bowel syndrome treated with teduglutide and weaning off home parenteral nutrition: a qualitative analysis of patient diaries.

    peer_reviewed_research

  158. 2025 · study · Temporal status not established

    Safety of Teduglutide for Managing Patients with Short Bowel Syndrome: A Systematic Review and Meta-analysis.

    systematic_review_or_meta_analysis

  159. 2025 · study · Temporal status not established

    Impact of teduglutide on pediatric short bowel syndrome: A systematic review and trial sequential meta-analysis.

    systematic_review_or_meta_analysis

  160. 2026 · study · Temporal status not established

    Teduglutide use in haemodialysis-dependent renal failure from secondary hyperoxaluria in short bowel syndrome and type 3 intestinal failure - A case report.

    peer_reviewed_research

  161. 2026 · study · Temporal status not established

    Clinical outcomes of teduglutide therapy in children with short bowel syndrome-associated intestinal failure: A single-center experience.

    peer_reviewed_research

  162. 2026 · study · Temporal status not established

    Real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure.

    peer_reviewed_research

  163. 2026 · study · Temporal status not established

    Successful treatment with teduglutide in short bowel syndrome with intestinal failure secondary to small-bowel volvulus: a case report and literature review.

    peer_reviewed_research

  164. 2026 · study · Temporal status not established

    Outcomes and adverse effects of teduglutide treatment with periodic withdrawal in pediatric short bowel patients.

    peer_reviewed_research

  165. 2026 · study · Temporal status not established

    Growth trajectories of children with short bowel syndrome during the first year of teduglutide treatment.

    peer_reviewed_research

  166. 2026 · study · Temporal status not established

    Development of a consensus parenteral solution weaning algorithm for children with short-bowel syndrome associated intestinal failure responding to teduglutide therapy.

    peer_reviewed_research

  167. 2026 · study · Temporal status not established

    Efficacy and safety of teduglutide in children with short bowel syndrome: a narrative review.

    peer_reviewed_research

  168. 2026 · study · Temporal status not established

    Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study.

    peer_reviewed_research

  169. 2026 · study · Temporal status not established

    Association between teduglutide treatment and long-term reductions in parenteral support: An observational cohort study of adults with short bowel syndrome.

    peer_reviewed_research

  170. 2026 · study · Temporal status not established

    Optimizing teduglutide treatment regimens in children with short bowel syndrome.

    systematic_review_or_meta_analysis

  171. 2026 · study · Temporal status not established

    Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide.

    peer_reviewed_research

  172. 2026 · study · Temporal status not established

    [Use of teduglutide in short bowel syndrome in infants, children and adolescents: Position paper of the working group "Chronic intestinal failure" of the Society for Paediatric Gastroenterology and Nutrition (GPGE)].

    systematic_review_or_meta_analysis

  173. 2026 · study · Temporal status not established

    Assessing the health-related quality of life and clinical effect in children with short bowel syndrome receiving teduglutide treatment.

    peer_reviewed_research

  174. 2026 · study · Temporal status not established

    A case report on the long-term use of teduglutide in a pediatric patient with short bowel syndrome.

    peer_reviewed_research

  175. 2026 · study · Temporal status not established

    Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance.

    peer_reviewed_research

  176. 2026 · regulatory · Temporal status not established

    Regulatory review: approved

    European Union — EMA

  177. 2026 · regulatory · Temporal status not established

    Regulatory review: approved

    United States — FDA

  178. 2027 · study · Temporal status not established

    Development of Teduglutide purity certified reference material (GBW09342) through amino acid-based isotope dilution mass spectrometry and sulfur-based isotope dilution inductively coupled plasma mass spectrometry.

    peer_reviewed_research

  179. Date unavailable · study · Temporal status not established

    Successful treatment with teduglutide for an adolescent with cerebral palsy accompanied by short bowel syndrome.

    other

  180. Date unavailable · study · Temporal status not established

    Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina.

    other

  181. Date unavailable · study · Temporal status not established

    Comment on "real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure".

    other

  182. Date unavailable · study · Temporal status not established

    PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.

    other

  183. Date unavailable · study · Temporal status not established

    Add-on to current guidelines for monitoring of SBS patients treated with teduglutide

    other

  184. Date unavailable · study · Temporal status not established

    Effectiveness and Safety of Teduglutide Treatment in Adult Patients with Short Bowel Syndrome: A Case Series and Review of Current Evidence.

    other

  185. Date unavailable · study · Temporal status not established

    Safety and long-term effectiveness of teduglutide in children with intestinal failure due to short bowel syndrome: a multicenter, post-marketing cohort study.

    other

  186. Date unavailable · study · Temporal status not established

    Teduglutide in Enterocolitis Secondary to Graft-Versus-Host Disease Post-Bone Transplant: Case Report

    other

  187. Date unavailable · study · Temporal status not established

    Real-world effectiveness and safety of teduglutide in patients with short bowel syndrome.

    other

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 3 represented connections ↓

institution

peer_reviewed_research

represented evidence source

institution

other

represented evidence source

institution

systematic_review_or_meta_analysis

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 6 domain conclusions and 0 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the Teduglutide evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:24:47 PM

global evidence atlas

Teduglutide research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

393Discoverable source universe
393Ranked screening records
6Research domains
0Accountably approved conclusions

393 matching records · ranked 2026-09-18

Page 1 of 16

Count reconciliation: 393 discoverable source records match the peptide identity query; 393 are retained in this bounded, ranked screening view; 0 belong to the separate governed layer labeled “Accountably approved conclusions.” Domain totals overlap because one publication may inform several questions.

governance and regulatory context

Teduglutide: what this atlas does and does not establish

Last checked
2026-09-18
Accountable publication approval
Not yet approved by a named accountable reviewer. Machine screening only.

No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.

1 FDA structured product label record(s) were identified for this compound name in openFDA. Label presence reflects an approved product exists under that name; it is not a claim about the specific formulation, dose, or use being discussed anywhere else on this page.

No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review.

Teduglutide evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

A

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

B

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

C

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

D

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

Suggested citation

  • APA

    World Peptide Foundation. (n.d.). Teduglutide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 26, 2026.) https://www.worldpeptidefoundation.org/directory/teduglutide

  • AMA / Vancouver

    World Peptide Foundation. Teduglutide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 26, 2026. https://www.worldpeptidefoundation.org/directory/teduglutide